TABLE OF CONTENTS

Welcome ............................................. 3
Leadership and Program Organizers ......... 4
Membership Information .......................... 7
About the Society ................................... 8
InterContinental Miami Hotel Floor Plans ... 9
Program At A Glance ............................. 10
General Information ................................ 13
Acknowledgments ................................... 16
Industry-Sponsored Symposia ................. 18
In-Conjunction-With Meetings ............... 19

PROGRAM

SATURDAY, 14 MAY
Education Course ................................. 21
Career Development Lunch ..................... 22

(pre-registration required)
Education Course Keynote Symposium ...... 23
Junior & Welcome Reception ..................... 24
(first hour reserved for Junior Members and
New Members only)

SUNDAY, 15 MAY
Peter J. Dyck Plenary Lecture .................. 25
Platform Session I ................................. 25
Oral Poster Session I .............................. 25
Richard & Mary Bunge Plenary Lecture ... 26
Platform Session II ............................... 26
Oral Poster Session II ............................ 27
Poster Session I .................................. 27
Guided Poster Hall Tours (Concurrent Sessions)
  Antibodies & Immunity ......................... 27
  Diagnostics & Imaging in Neuropathies .... 28
Special Interest Group (SIG) Concurrent Sessions
  Inflammatory Neuropathy Consortium (INC) .... 28
  Neuropathic Pain Consortium (NPC) ........ 31
CSL Behring Sponsored Symposium ........ 34
IONIS Sponsored Symposium ................ 34

MONDAY, 16 MAY
Alnylam Sponsored Symposium ............... 35
Grifols Sponsored Symposium ................ 35
Anita Harding Plenary Lecture ............... 36
Platform Session III ............................ 36
Oral Poster Session III ......................... 37
Jack Griffin Plenary Lecture ................ 37
Platform Session IV ............................. 38
Oral Poster Session IV .......................... 38
PNS Annual General Meeting .................. 38
(all are welcome)
Guided Poster Hall Tours (Concurrent Sessions)
  COVID/Vaccine Neuropathy .................. 39
  Stem Cells ...................................... 39
Special Interest Group (SIG) Concurrent Sessions
  Charcot-Marie-Tooth & Related ............. 40
    Neuropathies Consortium (CMTR)
    International Diabetes Neuropathy ....... 42
    Consortium (IDNC)
    Toxic Neuropathy Consortium (TNC) ...... 45
Pfizer Sponsored Symposium .................. 47
Takeda Sponsored Symposium .................. 47

TUESDAY
PK Thomas Plenary Lecture ................... 48
Platform Session V .............................. 48
Oral Poster Session V ........................... 48
Jonathan Pembroke Plenary Lecture ........ 49
Platform Session VI ............................. 49
Oral Poster Session VI .......................... 50
Poster Session II ................................ 50
Guided Poster Hall Tours (Concurrent Sessions)
  Fluid Biomarkers ............................... 50
  Trials & Therapies .............................. 51
Basic Science Highlights ........................ 51
Richard A.C. Hughes Symposium ............ 53
Clinical Highlights
Arthur K. Asbury/Presidential Plenary Lecture .............................. 54
Awards Ceremony ................................ 55
Closing Reception ............................... 55
Exhibitor Map ................................... 57
Exhibitor Directory ............................. 58
On behalf of the Peripheral Nerve Society, please let me welcome you to the 2022 Annual Meeting in Miami.

The PNS Annual Meeting continues to be the premier meeting for learning about advances in peripheral neuropathy and peripheral nerve biology. The Program Committee has organized a spectacular meeting with the traditional mixture of carefully selected plenary lectures, oral platforms, and oral posters, as well as symposia that were organized by the special interest groups — Charcot-Marie-Tooth and Related Neuropathies Consortium (CMTR), the Inflammatory Neuropathy Consortium (INC), the International Diabetes Neuropathy Consortium (IDNC), Neuropathic Pain Consortium (NPC), and the Toxic Neuropathy Consortium (TNC). We are excited to bring back the innovative clinical highlights and hold the basic science highlights sessions on Tuesday, 17 May.

We are excited to be meeting again in person this year finally. We’re bringing back the guided poster hall tours introduced in a virtual format in 2021 but will now be in person this year.

We also invite our Junior Members to participate in the Education Course and Career Development Lunch on Saturday, 14 May. New this year, the first hour of our Junior & Welcome Reception will be dedicated to Junior Members only (all others are invited to join after the first hour concludes).

I encourage you to attend the PNS Annual General Meeting on Monday, 15 May at 12.00 EDT (US and Canada). Your input is valuable as we discuss the current business and the future of the PNS.

Finally, don’t miss our exciting PNS Closing Reception to be held on the 5th floor pool deck of the hotel on Tuesday evening.

I want to personally thank the Scientific Program Committee, Local Organizing Committee, Junior Committee, PNS Board, staff, our sponsors, and everyone who has generously donated their time and efforts to put together the outstanding program of the meeting. I hope you will enjoy the 2022 PNS Annual Meeting and look forward to connecting with you there.

Richard Lewis, MD
President, Peripheral Nerve Society
PNS BOARD OF DIRECTORS

OFFICERS
Richard Lewis, MD, President, Cedars-Sinai, Los Angeles, CA, USA
Laura Feltri, MD, President-Elect, SUNY at Buffalo, Buffalo, NY, USA
Michael Polydefkis, MD, MHS, Secretary/Treasurer, Johns Hopkins Medicine, Baltimore, MD, USA
Pieter van Doorn, MD, PhD, Immediate Past President, Erasmus MC University Medical Center, Rotterdam, Netherlands

BOARD MEMBERS
Ahmet Hoke, MD, PhD, Johns Hopkins University, Baltimore, MD, USA
Stefano C. Previtali, MD, PhD, IRCCS San Raffaele Scientific Institute, Milan, Italy
Claudia Sommer, MD, Department of Neurology, University Hospital Würzburg, Würzburg, Germany
Charlotte Sumner, MD, Johns Hopkins Medicine, Baltimore, MD, USA
Peter Van den Bergh, MD, PhD, FEAN, FAAN, University Hospital St-Luc, Brussels, Belgium
Hugh Willison, MD, PhD, University of Glasgow, Glasgow, United Kingdom

Charcot-Marie-Tooth and Related Neuropathies Consortium (CMTR) Representative
Stephan Zuchner, MD, PhD, University of Miami, Miami, FL, USA

Inflammatory Neuropathy Consortium (INC) Representative
Chiara Briani, MD, University of Padova, Padova, Italy

International Diabetes Neuropathy Consortium (IDNC) Representative
James Russell, MD, MS, CAMC Institute for Academic Medicine, Charleston, WV, USA

Neuropathic Pain Consortium (NPC) Representative
Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA

Toxic Neuropathy Consortium Representative
Guido Cavaletti, MD, University of Milano-Bicocca, Monza, Italy

JPNS Editor in Chief
Giuseppe Lauria, MD, IRCCS FONDAZIONE ISTITUTO NEUROLOGICO CARLO BESTA & UNIVERSITY OF MILAN, Milano, Italy

Board Advisor
David Cornblath, MD, Johns Hopkins University, Baltimore, MD, USA

Junior Committee Representative
Kathryn Moss, PhD, Johns Hopkins University, Baltimore, MD, USA
SCIENTIFIC PROGRAM COMMITTEE

Scientific Program Committee Co-Chairs
Wendy Campana, PhD, UC San Diego/San Diego VA Health System, San Diego, CA, USA
Simon Rinaldi, PhD, University of Oxford, Oxford, United Kingdom

Clinical Highlights Chairs
David Cornblath, MD, Johns Hopkins University, Baltimore, MD, USA
Mary Reilly, MD, FRCP, FRCPI, FMedSci, University College London, London, United Kingdom

Basic Science Highlights Chairs
Elisabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA
Ruth Huizinga, PhD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands
Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

Prize Committee Chairs
Andrea Cortese, MD, PhD, Queen Square Centre for Neuromuscular Diseases, London, United Kingdom
Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA

CMTR Representative
Stephan Zuchner, MD, PhD, University of Miami, Miami, FL, USA

IDNC Representative
James Russell, MD, MS, CAMC Institute for Academic Medicine, Charleston, WV, USA

INC Representative
Chiara Briani, MD, University of Padova, Padova, Italy

TNC Representative
Guido Cavaletti, MD, University of Milano-Bicocca, Monza, Italy

NPC Representative
Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA

EAN Representative
Davide Pareyson, MD, Carlo Besta Neurological Institute IRCCS Foundation, Milan, Italy

Members
Paola Alberti, MD, PhD, University of Milano-Bicocca, Monza, Italy
Haesun Kim, PhD, Rutgers University Newark, NJ, USA
Kleopas Kleopa, MD, FAAN, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
Jun Li, MD, PhD, Wayne State University, Detroit, MI, USA
Kathryn Moss, PhD, Johns Hopkins University, Baltimore, MD, USA
Lucia Notterpek, PhD, University of Nevada, Reno School of Medicine, Reno, NV, USA
Luis Querol, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Maureen Su, MD, UCLA, Los Angeles, CA, USA
Charlotte Sumner, MD, Johns Hopkins Medicine, Baltimore, MD, USA
JUNIOR COMMITTEE
Kathryn Moss, PhD, Chair, Johns Hopkins University, Baltimore, MD, USA
Paola Alberti, MD, PhD, Vice-Chair, University of Milano-Bicocca, Monza, Italy
Mirlinda Ademi, MD, University of Cambridge, Cambridge, United Kingdom
Janev Fehmi, MD, NDCN University of Oxford, Oxford, United Kingdom
Tiffany Li, PhD Candidate, The University of Sydney, Sydney, Australia
Christian Moritz, PhD, Intitut NeuroMyoGène, University of Lyon / Saint-Étienne, Lyon, France
Marcus Pinto, MD, MS, Mayo Clinic, Rochester, MN, USA
Leena Shingavi, MD, PhD, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India
Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA
Luuk Wieske, MD, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands

PRIZE COMMITTEE
Andrea Cortese, MD, PhD, Co-Chair, Queen Square Centre for Neuromuscular Diseases, London, United Kingdom
Daniela Menichella, MD, PhD, Co-Chair, Northwestern University, Chicago, IL, USA
Christopher Gibbons, MD, MMSc, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Luis Querol, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Sandra Rieger, PhD, University of Miami, Miami, FL, USA
Charlotte Sumner, MD, Johns Hopkins Medicine, Baltimore, MD, USA
Douglas Wright, PhD, University of Kansas Medical Center, Kansas City, KS, USA
We invite you to join the Peripheral Nerve Society (PNS). The Society is dedicated to improving the lives of people with peripheral neuropathies throughout the world. Becoming a member of PNS means collaborating with prominent global professionals to develop and provide the best treatments for people with peripheral nerve diseases and setting standards of care within the field. PNS provides annual meetings, in-person and online teaching courses, guidelines, and other resources to aid in the education of members.

Membership in the Peripheral Nerve Society is open to any professional interested in disorders of the peripheral nervous system. Our membership includes clinicians, academicians, basic and clinical scientists, members of industry, and representatives from neuropathy organizations.

PNS Membership Features Include:

- Online subscription to *Journal of the Peripheral Nervous System (JPNS)*
- On-Demand Education Center Access
- Online Communities Forum Access
- PNS Membership Directory Access
- Member Only Job Postings
- Special Interest Group Memberships
- Volunteer & Leadership Opportunities
- Discounted Meeting & Event Registration Rates

Visit [www.PNSociety.com](http://www.PNSociety.com) for information on membership dues, categories, rates, and to join today. Please note: the PNS extends a membership discount to those joining the PNS from low-income and middle-income economies (GNI per capita of $12,535 or less).
The Peripheral Nerve Society (PNS) was founded in 1994 by two groups of academic investigators, the Peripheral Nerve Study Group and the Peripheral Neuropathy Association of America, interested in the basic biology and function of the peripheral nervous system and its application to the clinic. Their invite-only, biennial meetings involved 80-125 attendees in cloistered settings organized by shoestring and local initiatives. From this, we have grown remarkably. We now have an annual meeting of over 1000 people, including meetings within the meeting for the special interest groups in inflammatory, diabetic, toxic, pain, and hereditary neuropathy. With this substantial growth and the success of JPNS, the Journal of the Peripheral Nervous System, the Society continues to flourish. Please [click here](#) to view past meetings of the PNS.

We invite you to get involved in the PNS by volunteering for a project aligned with your interests. Have specific ideas? Please send them to the Executive Office at [info@PNSociety.com](mailto:info@PNSociety.com) or a Board Member.
## SATURDAY 14 MAY 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00-10.20</td>
<td>Coffee &amp; Registration</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>8.00-12.00</td>
<td>Inherited Neuropathy Meeting (Closed Meeting)</td>
<td>SANDRINGHAM/WINDSOR (2ND FLOOR)</td>
</tr>
<tr>
<td>9.00-10.15</td>
<td>IGOS Meeting (Closed Meeting)</td>
<td>RAPHAEL/MICHELANGELO (2ND FLOOR)</td>
</tr>
<tr>
<td>10.20-18.30</td>
<td><strong>Education Course</strong> <em>(All Are Welcome)</em></td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>10.20</td>
<td>Microphysiological Models of Peripheral Nerve</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>11.00</td>
<td>Basics of Nerve Conduction/Electromyography: From the Clinic to the Lab</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>11.40</td>
<td>Diagnosing and Misdiagnosing CIDP: Pitfalls and Red Flags</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>12.20-13.50</td>
<td>Lunch</td>
<td>GRAND BALLROOM FOYER (2ND FLOOR)</td>
</tr>
<tr>
<td>12.30-13.30</td>
<td><strong>IMAGiNe Study Consortium Q&amp;A Session</strong></td>
<td>RAPHAEL/MICHELANGELO (2ND FLOOR)</td>
</tr>
<tr>
<td>12.30-13.40</td>
<td>Career Development Lunch</td>
<td>TRIANON (2ND FLOOR)</td>
</tr>
<tr>
<td>13.40-15.10</td>
<td><strong>CMTR Workgroup Meeting</strong> <em>(All are welcome)</em></td>
<td>SANDRINGHAM/WINDSOR (2ND FLOOR)</td>
</tr>
<tr>
<td></td>
<td><strong>Education Course Cont.</strong> <em>(VERSAILLES (2ND FLOOR)</em></td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>13.50</td>
<td>Mechanisms and Consequences of De- vs. Dysmelination</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>14.30</td>
<td>Hallmarks of Non-CMT Inherited Neuropathies</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>15.10</td>
<td>Neuroinflammation: Mechanisms Leading to Axonal Damage and Neuropathic Pain in Chemotherapy-induced Peripheral Neurotoxicity</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>15.50</td>
<td>Pure Neural Leprosy</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>16.30-17.00</td>
<td>Coffee Break &amp; Exhibits</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>17.00-18.30</td>
<td><strong>Keynote Symposium:</strong> Nodes of Ranvier: From Assembly to Nodo-Paranodopathies <em>(three-part talk)</em></td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>17.00</td>
<td>Nodes, Paranodes and Juxtaparanodes: Normal Anatomy and Physiology</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>17.25</td>
<td>Immunology of the Node of Ranvier</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>17.50</td>
<td>Nodo-Paranodopathies: Clinical Phenotypes and Treatment</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>18.15</td>
<td>General Discussion (Q&amp;A)</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>19.00-22.00</td>
<td>Junior and Welcome Reception</td>
<td>PEREZ ART MUSEUM MIAMI (PAMM)</td>
</tr>
</tbody>
</table>

First hour is reserved for Junior Members and New Members only. Buses will depart from the InterContinental Miami Hotel lobby at 18.45

## SUNDAY 15 MAY 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.30-7.45</td>
<td>Coffee Break &amp; Exhibits</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>6.30-7.45</td>
<td>Poster Viewing</td>
<td>BISCAYNE BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>7.45-8.00</td>
<td>Presidential Welcome</td>
<td>GRAND BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>8.00-8.30</td>
<td><strong>Peter J Dyck Lecture:</strong> Diabetes</td>
<td>GRAND BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>8.30-9.30</td>
<td>Platform Session I</td>
<td>GRAND BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>9.30-10.00</td>
<td>Oral Poster Session I</td>
<td>GRAND BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Coffee Break &amp; Exhibits</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>10.30-11.00</td>
<td><strong>Richard and Mary Bunge Lecture:</strong> Biology of Nerve</td>
<td>GRAND BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td></td>
<td>Molecular Mechanisms Controlling PNS Myelin Formation and Maintenance</td>
<td>GRAND BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>11.00-11.45</td>
<td>Platform Session II</td>
<td>GRAND BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>11.45-12.00</td>
<td>Oral Poster Session II</td>
<td>GRAND BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>12.00-14.00</td>
<td>Lunch &amp; Exhibits</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>12.00-14.00</td>
<td><strong>Poster Session I</strong></td>
<td>BISCAYNE BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>Guided Poster Hall Tour: Antibodies &amp; Immunity</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>Guided Poster Hall Tour: Diagnostics &amp; Imaging in Neuropathies</td>
<td>TRIANON (2ND FLOOR)</td>
</tr>
<tr>
<td>14.00-19.00</td>
<td><strong>Special Interest Group (SIG) Concurrent Sessions</strong></td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>14.00</td>
<td>The Role of Complement in Immune Mediated Neuropathies</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>14.45</td>
<td>Biomarkers of Disease Activity in Immune-Mediated Neuropathies</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>15.30</td>
<td>Coffee Break &amp; Exhibits</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>16.00</td>
<td>Oral Poster Presentations</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>17.00</td>
<td><strong>INC Project Updates</strong></td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>17.30</td>
<td>Autoimmune Autonomic Neuropathies</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>18.15</td>
<td>Autoantibodies Associated with Paraneoplastic Neuropathies: Growing Spectrum and Relevance</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
</tbody>
</table>

**INFLAMMATORY NEUROPATHY CONSORTIUM (INC)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>The Role of Complement in Immune Mediated Neuropathies</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>14.45</td>
<td>Biomarkers of Disease Activity in Immune-Mediated Neuropathies</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>15.30</td>
<td>Coffee Break &amp; Exhibits</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>16.00</td>
<td>Oral Poster Presentations</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>17.00</td>
<td>INC Project Updates</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>17.30</td>
<td>Autoimmune Autonomic Neuropathies</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
<tr>
<td>18.15</td>
<td>Autoantibodies Associated with Paraneoplastic Neuropathies: Growing Spectrum and Relevance</td>
<td>VERSAILLES (2ND FLOOR)</td>
</tr>
</tbody>
</table>
SUNDAY 15 MAY 2022 (cont.)

Neuropathic Pain Consortium (NPC) TRIANON (2ND FLOOR)

14.00 Physiologic and Transcriptomic Findings in Human Dorsal Root Ganglia
Patrick Dougherty, PhD

14.30 Platform Presentations

15.00 Cannabinoids, Cannabis, and Cannabis-Based Medicines for Neuropathic Pain Management
Andrew Rice, MD, FRCP, FRCA

15.30 Coffee Break & Exhibits MEZZANINE (2ND FLOOR)

16.00 Skin in the Game: Keratinocytes Communicate with Sensory Neurons to Convey Pain
Cheryl Stucky, PhD

16.30 Oral Poster Presentations

17.00 Skin Biopsy in the Clinic
Claudia Sommer, MD

17.30 Platform Presentations

18.00 Sensory Neurons Modulate Skin Inflammation
Dan Kaplan, MD, PhD

18.30 Panel Discussion with all Speakers

19.00-19.15 Break MEZZANINE (2ND FLOOR)

19.15-20.15 Sponsored Symposia

CSL Behring Symposium TRIANON (2ND FLOOR)
IONIS Symposium VERSAILLES (2ND FLOOR)

MONDAY 16 MAY 2022

6.45-8.00 Coffee Break & Exhibits MEZZANINE (2ND FLOOR)

6.45-7.45 Sponsored Symposia

Alnylam Symposium CHOPIN (2ND FLOOR)
Grifols Symposium GRAND BALLROOM (2ND FLOOR)

8.00-8.30 Anita Harding Lecture: Female Pioneer
GRAND BALLROOM (2ND FLOOR)
The Role of Blood Neural Barriers in Motor Nerve Degeneration
Charlotte Sumner, MD

8.30-9.30 Platform Session III GRAND BALLROOM (2ND FLOOR)

8.30-9.30 Patient Advocacy Group (PAG) Meeting
(Closed Meeting) BALMORAL (2ND FLOOR)

9.30-10.00 Oral Poster Presentations III
GRAND BALLROOM (2ND FLOOR)

10.00-10.30 Coffee Break & Exhibits MEZZANINE (2ND FLOOR)

10.00-10.30 IGOS Biobank Meeting (Open Meeting)
BALMORAL (2ND FLOOR)

10.30-11.00 Jack Griffin Lecture: Regeneration
GRAND BALLROOM (2ND FLOOR)
The Schwann Cell-Associated Secretory Phenotype as a Therapeutic Target for Nerve Repair
Felipe A. Court, PhD

11.00-11.45 Platform Session IV
GRAND BALLROOM (2ND FLOOR)

11.45-12.00 Oral Poster Session IV
GRAND BALLROOM (2ND FLOOR)

12.00-12.30 PNS Annual General Meeting
(all are welcome) GRAND BALLROOM (2ND FLOOR)

12.30-14.00 Lunch & Exhibits MEZZANINE (2ND FLOOR)

13.00-13.30 Guided Poster Hall Tour: COVID/Vaccine Neuropathy
VERSAILLES (2ND FLOOR)

13.00-13.30 Guided Poster Hall Tour: Stem Cells
TRIANON (2ND FLOOR)

14.00-19.00 Special Interest Group (SIG) Concurrent Sessions

CHARCOT-MARIE-TOOTH & RELATED NEUROPATHIES CONSORTIUM (CMTR) VERSAILLES (2ND FLOOR)

14.00 An Update on Treating ATTR Amyloidosis
Isabel Conceição, MD

14.30 Platform Presentations

15.00 The Genetics of Pain-Related Neuropathies
Ingo Kurth, MD

15.30 Coffee Break & Exhibits MEZZANINE (2ND FLOOR)

16.00 Platform Presentations

16.30 Mechanistic Understanding and Therapeutic Discovery for Peripheral Neuropathy using Drosophila Models
Grace Zhai, PhD

17.00 Platform Presentations

17.30 Outcome Measures and Niomarkers in CMT for Successful Trial Readiness
David Herrmann, MBCh

18.00 Platform Presentations

18.30 Late Breaking Abstracts

INTERNATIONAL DIABETES NEUROPATHY CONSORTIUM (IDNC) CHOPIN (2ND FLOOR)

14.00 Welcome
James Russell, MD

14.05 Programmed Axon Death and Human Disease: Pathogenic and Therapeutic Implications in Diabetic Neuropathy
Michael Coleman, PhD

14.50 Platform Presentations

15.30 Coffee Break & Exhibits MEZZANINE (2ND FLOOR)

16.00 Emerging Biomarkers in Diabetic Neuropathy
Vera Fridman, MD

16.45 Neuroimmune Regulation of Remission and Relapse of Neuropathic Pain
Geoffroy Laumet, PhD

17.30 Inflammation as a Therapeutic Target for Diabetic Peripheral Neuropathy
Rodica Pop-Busui, MD, PhD

18.15 Oral Poster Presentations

18.40 The Unmet Need for Disease Modification in Diabetic Peripheral Neuropathy. First Steps: The Taxonomy Project
Roy Freeman, MD

18.55 Closing Remarks
James Russell, MD
### MONDAY 16 MAY 2022 (cont.)

**TOXIC NEUROPATHY CONSORTIUM (TNC)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>Emerging Mechanisms of Nerve Damage in CIPN</td>
<td>TRIANON (2ND FLOOR)</td>
</tr>
<tr>
<td></td>
<td>Nathan Staff, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>14.30</td>
<td>Different Approaches to CIPN Assessment: Serum Biomarkers</td>
<td>TRIANON (2ND FLOOR)</td>
</tr>
<tr>
<td></td>
<td>Paola Alberti, MD</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Apps and Wearables for Remote CIPN Monitoring</td>
<td>TRIANON (2ND FLOOR)</td>
</tr>
<tr>
<td></td>
<td>Daniel Hertz, PharmD, PhD</td>
<td></td>
</tr>
<tr>
<td>15.10</td>
<td>General Discussion</td>
<td></td>
</tr>
<tr>
<td>15.30</td>
<td>Coffee Break &amp; Exhibits</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>16.00</td>
<td>Update on TNC Activities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guido Cavaletti, MD</td>
<td></td>
</tr>
<tr>
<td>16.30</td>
<td>Platform Presentations</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.30-16.00</td>
<td>JPNS Editorial Board Meeting (Closed Meeting)</td>
<td>BALMORAL (2ND FLOOR)</td>
</tr>
<tr>
<td>19.00-19.15</td>
<td>Break</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>19.15-20.15</td>
<td>Sponsored Symposia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pfizer Symposium</td>
<td>TRIANON</td>
</tr>
<tr>
<td></td>
<td>Takeda Symposium</td>
<td>VERSAILLES</td>
</tr>
<tr>
<td>20.15-21.15</td>
<td>IDNC Board Meeting (Closed Meeting)</td>
<td>BALMORAL (2ND FLOOR)</td>
</tr>
</tbody>
</table>

### TUESDAY 17 MAY 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.45-8.00</td>
<td>Coffee Break &amp; Exhibits</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>6.45-8.00</td>
<td>Poster Viewing</td>
<td>BISCAYNE BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>8.00-8.30</td>
<td>PK Thomas Lecture: Inherited Neuropathies</td>
<td>GRAND BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td></td>
<td>Gene Therapies for Inherited Demyelinating Neuropathies</td>
<td>Kleopas Kleopa, MD, FAAN</td>
</tr>
<tr>
<td>8.30-9.30</td>
<td>Platform Session V</td>
<td>GRAND BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>9.30-10.00</td>
<td>Oral Poster Session V</td>
<td>GRAND BALLROOM (2ND FLOOR)</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Coffee Break &amp; Exhibits</td>
<td>MEZZANINE (2ND FLOOR)</td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>TNC Board Meeting (Closed Meeting)</td>
<td>BALMORAL (2ND FLOOR)</td>
</tr>
</tbody>
</table>

### WEDNESDAY 18 MAY 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.30-8.30</td>
<td>CMTR Board Meeting (Closed Meeting)</td>
<td>ESCORIAL (2ND FLOOR)</td>
</tr>
<tr>
<td>7.30-8.30</td>
<td>INC Board Meeting (Closed Meeting)</td>
<td>RAPHAEL/MICHAELANGELO (2ND FLOOR)</td>
</tr>
<tr>
<td>9.00-12.00</td>
<td>PNS Board Meeting (Closed Meeting)</td>
<td>RAPHAEL/MICHAELANGELO (2ND FLOOR)</td>
</tr>
</tbody>
</table>
GENERAL INFORMATION

REGISTRATION/HELP DESK HOURS (MEZZANINE / SECOND FLOOR)
Saturday, 14 May 8.00-19.00
Sunday, 15 May 6.30-19.00
Monday, 16 May 6.30-19.00
Tuesday, 17 May 6.45-17.30

SPEAKER READY ROOM (OXFORD / SECOND FLOOR)
All speakers must upload their presentations here at least 90 minutes before the session starts.

Saturday, 14 May 8.00-19.00
Sunday, 15 May 6.00-20.30
Monday, 16 May 6.00-20.30
Tuesday, 17 May 6.30-17.30

*Note: Speaker designations are listed in the program, as submitted

CERTIFICATE OF ATTENDANCE
Your certificate of attendance will be emailed to you after the meeting upon completion of the meeting evaluation.

IN PERSON REGISTRATION FEES
Registration fees include:
• Saturday Education Course
• Three full days of regular programming with special interest group afternoon sessions
• Two exciting receptions
• Access to exhibit hall and directory
• Access to on-demand content and E-Poster Hall through 31 December 2022
• A chance to network with friends, old and new
• Breakfast, Lunch, and Coffee breaks

NAME BADGE
All participants (including guests) are required to wear their name badge at all PNS sanctioned events.
FACE MASK POLICY
To protect the safety of our community, all attendees (including guests) are required to wear a face mask at all PNS sanctioned events. Those participating in a panel discussion or speaking from the podium will be exempt. Attendees will also not be required to wear a mask while actively eating or drinking.

LIABILITY & INSURANCE
The organizers accept no responsibility for any injury or damage involving persons and property during the 2022 PNS Meeting.

MOBILE APP INFORMATION
Navigate the event like a pro with the PNS 2022 Annual Meeting mobile app, powered by Core-apps.com.

With the PNS 2022 Annual Meeting app, you can:
• Stay organized with up-to-the-minute speaker, exhibitor and event information
• Receive critical real-time communications from PNS
• Build a personalized schedule and bookmark exhibitors
• Take notes
• Stay in-the-know and join in on social media with #PNS2022
• Share your event photos and experience with the Photo Gallery
• And much, much more!

DOWNLOADING THE APP IS EASY!
While on your smartphone, visit https://bit.ly/3Lv4cUd to download the mobile app to your device.

Access the Complimentary WiFi at the InterContinental Miami
(Available in PNS Meeting Space)
Network: ICConnect
Password: Miami2022 (case sensitive)
GENERAL INFORMATION

EXHIBITION
Please be sure to visit the exhibits located in the Mezzanine (2nd Floor) at the breaks. View the Exhibitor Directory on page 58. All catering services will be located here. Exhibits open at 16.30 on Saturday, 14 May.

POSTER SESSIONS
Poster Session I: Sunday, 15 May
Room: Biscayne Ballroom (2nd Floor)
Mandatory Stand by Time: 12.00-14.00
Poster Set Up: 17.30-19.00 on Saturday, 14 May
Poster Dismantle: 10.00-10.30 on Monday, 16 May

Poster Session II: Tuesday, 17 May
Room: Biscayne Ballroom (2nd Floor)
Mandatory Stand by Time: 12.00-14.00
Poster Set Up: 12.00-13.00 on Monday, 16 May
Poster Dismantle: 14.00-15.00 on Tuesday, 17 May

SOCIAL MEDIA
Share your excitement about the PNS Annual Meeting using #PNS2022 on Twitter and Facebook.

ON-DEMAND PROGRAMMING
On-demand content will be available 5 business days after it has aired live (by 25 May). All plenary talks, education course talks, and sponsored symposia talks are being recorded for on-demand viewing.

E-POSTER HALL
The PNS e-poster hall will be available for viewing thru 31 December 2022.
We thank the generosity of our sponsors and exhibitors. This meeting would not be possible without their support.
ACKNOWLEDGEMENTS

BRONZE SPONSORS

EXHIBITORS

PATIENT ADVOCACY GROUPS (PAGS)
INDUSTRY-SPONSORED SYMPOSIA

We invite you to join each of our Annual Partners for their industry-sponsored symposium.

SUNDAY, 15 MAY

CSL Behring Symposium: Use of Immunoglobulin in the Individualized Management of CIDP
19.15-20.15  TRIANON BALLROOM (2ND FLOOR)

IONIS Symposium: Mixed Phenotype ATTR Amyloidosis: Are we Seeing the Whole Patient?
19.15-20.15  VERSAILLES BALLROOM (2ND FLOOR)

MONDAY, 16 MAY

Alnylam Symposium: Understanding, Diagnosing, and Treating the Polyneuropathy of hATTR Amyloidosis
6.45-7.45  CHOPIN BALLROOM (2ND FLOOR)

Grifols Symposium: Immunoglobulins in CIDP: Mechanisms of Action and New Genetic Insights
6.45-7.45  GRAND BALLROOM (2ND FLOOR)

Pfizer Symposium: An Intravenous Immunoglobulin Treatment With 2 FDA-Approved Maintenance Dosing Options for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
19.15-20.15  TRIANON BALLROOM (2ND FLOOR)

Takeda Symposium: A Practical Approach to Diagnosis and Management of MMN: Past, Present and Future
19.15-20.15  VERSAILLES BALLROOM (2ND FLOOR)
IN-CONJUNCTION-WITH MEETINGS

SATURDAY, 14 MAY 2022

08.00-12.00  Inherited Neuropathy Meeting  SANDRINGHAM/WINDSOR (2ND FLOOR)  
This is a closed meeting.

09.00-10.15  IGOS Meeting  RAPHAEL/MICHELANGELO (2ND FLOOR)  
This is a closed meeting.

12.30-13.30 IMAGiNe Study Consortium Q&A Session  RAPHAEL/MICHELANGELO (2ND FLOOR)  
This is a closed meeting.

13.40-15.10 CMTR Workgroup Meeting  SANDRINGHAM/WINDSOR (2ND FLOOR)  
All are welcome.

MONDAY, 16 MAY 2022

08.30-9.30 Patient Advocacy Group (PAG) Meeting  BALMORAL (2ND FLOOR)  
This is a closed meeting.

10.00-10.30 IGOS Biobank Meeting  BALMORAL (2ND FLOOR)  
This is an open meeting.

15.30-16.00 JPNS Editorial Board Meeting  BALMORAL (2ND FLOOR)  
This is a closed meeting.

20.15-21.15 International Diabetes Neuropathy Consortium (IDNC) Board Meeting  
BALMORAL (2ND FLOOR)  This is a closed meeting.

TUESDAY, 17 MAY 2022

10.00-10.30 Toxic Neuropathy Consortium (TNC) Board Meeting  BALMORAL (2ND FLOOR)  
This is a closed meeting.

16.00-16.30 PNS Prize Committee Meeting  GROVE (1ST FLOOR)  
This is a closed meeting.

16.00-16.30 PNS Annual Partner Roundtable Meeting  BALMORAL (2ND FLOOR)  
This is a closed meeting.

17.30-18.30 Neuropathic Pain Consortium (NPC) Board Meeting  BALMORAL (2ND FLOOR)  
This is a closed meeting.

WEDNESDAY, 18 MAY 2022

07.30-08.30 Charcot-Marie-Tooth & Related Neuropathies (CMTR) Board Meeting  
ESCORIAL (2ND FLOOR)  This is a closed meeting.

07.30-08.30 Inflammatory Neuropathy Consortium INC) Board Meeting  
RAPHAEL/MICHELANGELO (2ND FLOOR)  This is a closed meeting.

09.00-12.00 Peripheral Nerve Society Board Meeting  RAPHAEL/MICHELANGELO (2ND FLOOR)  
This is a closed meeting.
Schedule
8.00-10.20 Coffee & Registration  MEZZANINE
8.00-12.00 Inherited Neuropathy Meeting  SANDRINGHAM/WINDSOR ROOM
This is a closed meeting.
9.00-10.15 IGOS Meeting  MICHAELANGELO/raphael room
This is a closed meeting.
10.20-18.30 Education Course (All Are Welcome)  VERSAILLES BALLROOM

**Chairs:** Kathryn Moss, PhD, Johns Hopkins University, Baltimore, MD, USA and Luuk Wieske, MD, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands

10.20 Microphysiological Models of Peripheral Nerve
Michael J. Moore, PhD
Tulane University/AxoSim, New Orleans, LA, USA

11.00 Basics of Nerve Conduction/Electromyography: From the Clinic to the Lab
Paola Alberti, MD, PhD
University of Milano-Bicocca, Monza, Italy, and David Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA

11.40 Diagnosing and Misdiagnosing CIDP: Pitfalls and Red Flags
Jeffrey Allen, MD
University of Minnesota, Minneapolis, MN, USA
PROGRAM – SATURDAY, 14 MAY 2022

12.20-13.50 Lunch GRAND BALLROOM FOYER

12.30-13.30 IMAGiNe Study Consortium Q&A Session RAPHAEL/MICHELANGELO
This is a closed meeting.

12.30-13.40 Career Development Lunch TRIANON BALLROOM
Pre-Registration Required
Hosted by the PNS Junior Committee, this event aims to provide junior investigators with an opportunity to discuss funding opportunities, career paths, and more in a small group setting with experts in the peripheral nerve field. Lunch will be provided.

13.40-15.10 CMTR Workgroup Meeting SANDRINGHAM/WINDSOR
All are welcome.

13.50-16.30 Education Course continued VERSAILLES BALLROOM
Chairs: Paola Alberti, MD, PhD, University of Milano-Bicocca, Monza, Italy, and Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

13.50 Mechanisms and Consequences of De- vs. Dysmelination
Jun Li, MD, PhD
Wayne State University, Detroit, MI, USA

14.30 Hallmarks of Non-CMT Inherited Neuropathies
Vera Fridman, MD
University of Colorado, Englewood, CO, USA

15.10 Neuroinflammation: Mechanisms Leading to Axonal Damage and Neuropathic Pain in Chemotherapy-induced Peripheral Toxicity
Guido Cavaletti, MD
University of Milano-Bicocca, Monza, Italy
**PROGRAM – SATURDAY, 14 MAY 2022**

15.50  **Pure Neural Leprosy**  
Wilson Marques Junior, MD, PhD  
*Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil*

16.30-17.00  **Coffee Break & Exhibits**  
MEZZANINE

17.00-18.30  **Education Course Keynote Symposium: Nodes of Ranvier: From Assembly to Node-Paranodopathies (three-part talk)**  
*VERSAILLES BALLROOM*  
**Chairs:** Divyanshu Dubey, MD, Mayo Clinic, Rochester, MN, USA, and Marcus Pinto, MD, MS, Mayo Clinic, Rochester, MN, USA

17.00  **Nodes, Paranodes and Juxtaparanodes: Normal Anatomy and Physiology**  
Kleopas Kleopa, MD, FAAN  
*The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus*

17.25  **Immunology of the Node of Ranvier**  
Luis Querol, MD, PhD  
*Hospital de la Santa Creu i Sant Pau, Barcelona, Spain*

17.50  **Nodo-Paranodopathies: Clinical Phenotypes and Treatment**  
Antonino Uncini, MD  
*University “G. D’Annunzio” Chieti-Pescara, Italy, Monsampolo del Tronto, Italia*

18.15  **General Discussion (Q&A)**
Help us honor our Junior and New Members of the Society by joining us at the Perez Art Museum Miami. **The first hour (19.00-20.00) of this Junior and Welcome Reception is reserved only for Junior Members and New Members.** All conference delegates are invited to attend starting at 20.00 (don’t miss the special champagne toast and welcome from the PNS President!).

Heavy appetizers, drinks, and live entertainment will be provided.

The PNS has reserved the entire museum for PNS meeting attendees to walk and explore. The Perez Art Museum will be debuting its newest exhibit: *Marisol and Warhol Take New York*. PNS members will have one hour (20.00-21.00) of exclusive access to the museum exhibits, including *Marisol and Warhol Take New York*. The PNS has arranged for museum docents to be available.

The PAMM is conveniently located approximately 1 mile from the InterContinental Miami (transportation will be provided).

Perez Art Museum Miami Address:
1103 Biscayne Blvd, Miami, FL 33132

**Timing:**

19.00-20.00: Reserved for Junior & New Members Only

20.05-21.00: Exhibits Open for PNS Members to View: *Marisol and Warhol Take New York* (Docents Available) & Reception

21.00-22.00: Reception Continues/DJ
PROGRAM – SUNDAY, 15 MAY 2022

6.30-7.45 Coffee Break & Exhibits MEZZANINE

6.30-7.45 Poster Viewing BISCAYNE BALLROOM

7.45-8.00 Presidential Welcome GRAND BALLROOM
Richard Lewis, MD, Cedars-Sinai, Los Angeles, CA, USA

8.00-8.30 Peter J. Dyck Plenary Lecture: Diabetic Neuropathy: Light at the End of the Funnel? GRAND BALLROOM
Nigel Calcutt, PhD
University of California San Diego, San Diego, CA, USA

Chairs:
Mirlinda Ademi, MD
University of Cambridge, Cambridge, United Kingdom, and
Brian Callaghan, MD, MS
University of Michigan, Ann Arbor, MI, USA

8.30-9.30 Platform Session I GRAND BALLROOM
Chairs: Mirlinda Ademi, MD, University of Cambridge, Cambridge, United Kingdom, and Brian Callaghan, MD, MS, University of Michigan, Ann Arbor, MI, USA

8.30 The Effect of Surgical Weight Loss on Neuropathy in the Severely Obese
Evan Reynolds, PhD, University of Michigan, Ann Arbor, MI, USA

8.45 Comparison Of Three State of the Art Small Fibre Measures in Type 2 Diabetic Polyneuropathy
Troels Jensen, MD, PhD, Aarhus University, Aarhus, Denmark

9.00 Administration of AICAR, an AMPK Activator, Prevents and Reverses Diabetic Polyneuropathy (DPN) by Regulating Mitophagy
Krish Chandrasekaran, PhD, University of Maryland School of Medicine, Baltimore, MD, USA

9.15 Metformin and Resistance Exercise Alleviate Stress-Induced Peripheral Injury in Type 2 Diabetes
Lynn Ala‘eddine, MSc/PhD Candidate, American University of Beirut, Beirut, Lebanon

9.30-10.00 Oral Poster Session I GRAND BALLROOM
Chairs: Brian Callaghan, MD, MS, University of Michigan, Ann Arbor, MI, USA, and Mirlinda Ademi, MD, University of Cambridge, Cambridge, United Kingdom

9.30 Sirtuin1 Mediated Deacetylation of E3 Ubiquitin Ligase NEDD4-1 Regulates Axonal Growth and Treats Diabetic Peripheral Neuropathy
Krish Chandrasekaran, PhD, University of Maryland School of Medicine, Baltimore, MD, USA
9.35 Ketone Metabolism in the Peripheral Nerve Contributes to the Analgesic Effect of a Ketogenic Diet
Jonathan Enders, University of Kansas Medical Center, Kansas City, MO, USA

9.40 Vagal Afferent Free Fatty Acid Receptor 3 (FFAR3) Regulates Feeding Behavior
Tyler Cook, BS, Loyola University Chicago, Maywood, IL, USA

9.45 Activation of 20-HETE Synthase Triggers Oxidative Injury and Peripheral Nerve Damage in Type 2 Diabetic Mice
Assaad A. Eid, Prof., American University of Beirut, Beirut, Lebanon

9.50 Structural Alterations Reduce Nociception in Mice Carrying the L799P-Gain-of-Function Variant in NaV1.9 Sodium Channel
Annika Schmidt, Institute of Human Genetics, Aachen, Germany

9.55 Pharmacological Inhibition of GCN2 is Efficacious in Mouse Models of CMT2D
Robert Burgess, PhD, The Jackson Laboratory, Bar Harbor, ME, USA

10.00-10.30 Coffee Break & Exhibits MEZZANINE

10.30-11.00 Richard & Mary Bunge Plenary Lecture: Molecular Mechanisms Controlling PNS Myelin Formation and Maintenance GRAND BALLROOM

Carla Taveggia, PhD
San Raffaele Hospital, Milan, Italy

Chairs:
Elisabetta Babetto, PhD
SUNY at Buffalo, Buffalo, NY, USA, and
Laura Feltri, MD
SUNY at Buffalo, Buffalo, NY, USA

11.00-11.45 Platform Session II GRAND BALLROOM
Chairs: Elisabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA, and
Laura Feltri, MD, SUNY at Buffalo, Buffalo, NY, USA

11.00 Post-Onset Gene Therapy Improves Myelination in a CMT4C Model
Kleopas Kleopa, MD, FAAN, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

11.15 Clinical and Pathophysiological Characterization of Anti-Pan-Neurofascin Associated Nodo-Paranodopathy
Luise Appeltshauser, MD, Msc, Universitätsklinikum Würzburg, Wuerzburg, Germany

11.30 Gli1 Regulates the Postnatal Acquisition of Peripheral Nerve Architecture
Brendan Zotter, PhD, New York University School of Medicine, New York, NY, USA
11.45-12.00  **Oral Poster Session II** GRAND BALLROOM  
**Chairs:** Elisabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA, and Laura Feltri, MD, SUNY at Buffalo, Buffalo, NY, USA

- **11.45** Schwann Cell LRP1 is Essential for Conserving Myelin and Mitochondrial Integrity in Aged Peripheral Nerves  
  Melissa Heredia, MS, University of California San Diego, La Jolla, CA, USA

- **11.50** Mitochondrial Dysfunction is a Feature Of Paclitaxel and Oxaliplatin-Promoted Chemotherapy-Induced Peripheral Neurotoxicity  
  Silvia Giatti, PhD, Università degli studi di Milano, Milano, Italy

- **11.55** Human iPSC-Derived Organoid Model Recapitulates Rescuable Key Pathology Features of CMT1A  
  Jonas Van lent, University of Antwerp, Antwerp, Belgium

12.00-14.00 Lunch & Exhibits MEZZANINE

12.00-14.00  **Poster Session I** BISCAYNE BALLROOM

13.00-13.30  **Guided Poster Hall Tour: Antibodies & Immunity** VERSAILLES BALLROOM  
**Chairs:** Luise Appeltshauser, MD, Msc, Universitätsklinikum Würzburg, Wuerzburg, Germany, and Luis Querol, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

- **13.00** Autoantibody Studies in the CIDP01/CIDP04 Clinical Trials  
  Cinta Lleixà, Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

- **13.04** Autoantibody Screening in Neuralgic Amyotrophy Patients  
  Lorena Martin-Aguilar, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

- **13.08** A Diagnostic Score for the Diagnosis of Anti-MAG Neuropathy or CIDP in Patients with High Titers of Anti-MAG Antibodies  
  Pietro Doneddu, MD, IRCCS Humanitas Research Hospital, Milano, Italy

- **13.12** In Vitro Anti-Glycolipid Antibody Production by Guillain-Barré Syndrome Patients’ Derived B Cells  
  Ruth Huizinga, PhD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

- **13.16** Acute Relapsing Ataxic Sensory Neuronopathy with anti-FGFR3 Autoantibodies Mimicking Acute Myelopathy  
  Julian Theuriet, Hospices Civils de Lyon, Lyon, France

- **13.20** General Discussion (Q&A)
13.00-13.30  Guided Poster Hall Tour: Diagnostics & Imaging in Neuropathies
TRIANON BALLROOM
Chairs: Chiara Briani, MD, University of Padova, Padova, Italy and Stephan Goedee, MD, PhD, UMC Utrecht, Utrecht, Netherland

13.00  Electrodiagnostic Subtyping in Guillain-Barré Syndrome: Application of Criteria by Neuromuscular Specialists in Current Clinical Practice
Samuel Arends, Leidschendam, Netherlands

13.04  Serum Peripherin is Superior to NFL as a Biomarker for Axonal Damage in Inflammatory Peripheral Nerve Disease
Ryan Keh, MRCP, MBBCHIR, MRC Centre for Neuromuscular Diseases, London, United Kingdom

13.08  The Effects of Implementing the EAN/PNS Guideline (Second Revision) on Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy
Iris van Doorn, MD, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands

13.12  Magnetic Resonance Neurography and Diffusion Tensor Imaging of the Sciatic Nerve in Hereditary Transthyretin Amyloidosis Polyneuropathy
Alessandro Salvalaggio, MD, Department of Neuroscience, University of Padova, Padova, Italy

13.16  A Cross-Sectional Analysis of Spinal MRI Findings in UK hATTR
Luke O’Donnell, MB, BCh, BAO, University College London, London, United Kingdom

13.20  General Discussion (Q&A)

14.00-19.00  SPECIAL INTEREST GROUP (SIG) CONCURRENT SESSIONS – INC & NPC

14.00-19.00  INFLAMMATORY NEUROPATHY CONSORTIUM (INC) VERSAILLES BALLROOM

14.00  The Role of Complement in Immune-Mediated Neuropathies
Peter J Spaeth, PhD
Institute of Pharmacology, University of Berne, Berne, Switzerland

Chair:
Luis Querol, MD, PhD
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
PROGRAM – SUNDAY, 15 MAY 2022

14.45  Biomarkers of Disease Activity in Immune-Mediated Neuropathies
       Jeffrey Allen, MD
       University of Minnesota, Minneapolis, MN, USA

       Chair:
       Ruth Huizinga, PhD
       Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

15.30  Coffee Break & Exhibits MEZZANINE

16.00  Oral Poster Presentations
       Chairs: Karissa Gable, MD, Duke University, Durham, NC, USA, and
              Richard Lewis, MD, Cedars-Sinai, Los Angeles, CA, USA

16.00  Pathophysiological Effects of Anti-Neurofascin155 IgG3 and
       IgG4 In Vivo
       Katharina Hecker, Neurology, University Hospital Würzburg,
       Würzburg, Germany

16.05  Neuropathies Amidst the Pandemic: Remote Assessment of
       Patient Needs and Phenotype Validation
       Maike Dohrn, MD, Hussman Institute for Human Genomics
       and Department of Human Genetics, Miller School of Medicine,
       University of Miami, Miami, FL, USA; Department of Neurology,
       Medical Faculty of the RWTH Aachen University Hospital,
       Aachen, Germany

16.10  Proteomics Based Discovery of Biomarkers For Disease Activity
       In CIDP
       Luuk Wieske, MD, PhD, Amsterdam University Medical Centers,
       Amsterdam, Netherlands

16.15  Autoantibody Screening in Idiopathic Small-Fiber Neuropathy
       Elba Pascual-Goñi, MD PhD, Hospital de la Santa Creu i Sant Pau,
       Barcelona, Spain

16.20  Skin Biopsy Parameter-Driven Phenotyping of Autoimmune
       Neuropathies
       Young Gi Min, MD, Department of Translational Medicine, Seoul
       National University College of Medicine, Seoul, Republic of Korea

16.25  Diagnostic Value of Standardized Nerve Ultrasound of the
       Plexus Brachialis in Chronic Inflammatory Neuropathies
       Nicolas Dubuisson, Woluwe St-Lambert, Belgium

16.30  IVIg-Exposure and Thromboembolic Event Risk: Findings from
       the UK Biobank
       Mahima Kapoor, MBBS, FRACP, Alfred Hospital, Monash
       University Prahran, Victoria, Australia
**16.35**  
*Gut Microbiota as a Therapeutic Target to Ameliorate Neural Injury in Autoimmune Neuropathy*  
Gang Zhang, PhD, *The University of Texas Health Science Center at Houston, Houston, TX, USA*

**16.40**  
*CSF IL-8 in Acute and Chronic Inflammatory Polyneuropathies*  
Ivan Kmezic, *Karolinska Institutet, Department of Clinical Neuroscience, Stockholm, Sweden*

**16.45**  
*Single Nucleotide Polymorphisms in Cytokine Genes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy*  
Ivo Bozovic, *Belgrade, Serbia*

**16.50**  
*Update on the Dutch Guillain-Barré syndrome Mimics Study*  
Linda Luijten, MD, *Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands*

**16.55**  
*Early Recognition of Guillain-Barré Syndrome with Treatment-Related Fluctuations and Acute-Onset Chronic Inflammatory Demyelinating Polyneuropathy*  
Linda Luijten, MD, *Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands*

**17.00**  
**INC Project Updates**

**17.00**  
**Chair Welcome**  
Chiara Briani, MD, *University of Padova, Padova, Italy*

**17.05**  
*Update on IMAGiNe Study: The IgM M-protein Associated Neuropathy International Registry*  
Tatiana Hamadeh, PhD, *Maastricht University Medical Centre, Maastricht, Netherlands*

**17.10**  
*Update on INCbase*  
Filip Eftimov, MD, PhD, *Amsterdam University Medical Center, Amsterdam, Netherlands*

**17.15**  
*Update on IGOS*  
Bart Jacobs, MD, *Erasmus MC, Rotterdam, Netherlands*

**17.20**  
*Italian CIDP and MMN Databases and Rituximab Trials: Where We Are*  
Eduardo Nobile-Orazio, MD, PhD, *IRCCS Humanitas Research Hospital, Rozzano, Milan University, Italy,* and Pietro Doneddu, MD, *IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy*

**17.25**  
*Grant Opportunities Available through the GBS | CIDP Foundation*  
Lisa Butler, *Executive Director, GBS | CIDP Foundation International, Conshohocken, PA, USA*
17.30 Autoimmune Autonomic Neuropathies Valeria Iodice, MD, PhD Autonomic Unit, University College London, London, United Kingdom
Chair: Robert Hadden, MA, BM BCh, FRCP, PhD King’s College Hospital, London, United Kingdom

18.15 Autoantibodies Associated with Paraneoplastic Neuropathies: Growing Spectrum and Relevance Divyanshu Dubey, MD Mayo Clinic, Rochester, MN, USA Chair: Christopher Klein, MD Mayo Clinic, Rochester, MN, USA

14.00-19.00 NEUROPATHIC PAIN CONSORTIUM (NPC) TRIANON BALLROOM
14.00 Physiologic and Transcriptomic Findings in Human Dorsal Root Ganglia Patrick Dougherty, PhD The University of Texas M.D. Anderson Cancer Center, Pearland, TX, USA
Chairs: Theodore Price, PhD University of Texas at Dallas, Dallas, TX, USA, and Grace Shin, PhD Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

14.30 Platform Presentations
Chairs: Theodore Price, PhD, University of Texas at Dallas, Dallas, TX, USA, and Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

14.30 Real Time Imaging of Mitochondrial Dynamics in the Dorsal Root Ganglion Following Nerve Injury Juliet Mwirigi, BS, Richardson, TX, USA

14.40 Microtubule Acetylation Rescues Capsaicin-Induced Neurite Degeneration and May Predict Fiber Regeneration Daniele Cartelli, PhD, Neuroalgology Unit, Fondazione IRCCS Istituto Neurologo Carlo Besta, Milano, Italy
14.50 Neuron-Keratinocyte Communication in the Epidermis in Painful Diabetic Neuropathy
Dale George, PhD, Northwestern University, Chicago, IL, USA

15.00 Cannabinoids, Cannabis, and Cannabis-Based Medicines for Neuropathic Pain Management
Andrew Rice, MD, FRCP, FRCA
Imperial College, London, United Kingdom

Chairs:
James Russell, MD, MS
CAMC Institute for Academic Medicine, Charleston, WV, USA, and
Stefano Tamburin, MD, PhD
University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Verona, Italy

15.30 Coffee Break & Exhibits MEZZANINE

16.00 Skin in the Game: Keratinocytes Communicate with Sensory Neurons to Convey Pain
Cheryl Stucky, PhD
Medical College of Wisconsin, Franklin, WI, USA

Chairs:
Daniele Cazzato, MD, PhD
IRCCS Foundation “C. Besta” Neurological Institute, Milan, Italy, and
Daniela Maria Menichella, MD, PhD
Northwestern University, Chicago, IL, USA

16.30 Oral Poster Presentations
Chairs: Daniele Cazzato, MD, PhD, IRCCS Foundation “C. Besta” Neurological Institute, Milan, Italy, and Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA

16.30 Comparison of Amyloid Detection in the Skin and Tenosynovium of Transthyretin Amyloidosis Patients
Amrita Daniel, MBBS, D Ortho, Johns Hopkins School of Medicine, Baltimore, MD, USA

16.35 Evaluation of Sex-Related Differences in Oxaliplatin-Induced Changes in the Expression of Endocannabinoid Receptors and Enzymes in Lumbar Ganglia
Maria Coronel, PhD, IIMT CONICET - Austral Pilar, Buenos Aires, Argentina

16.40 Sensory Quantification Suggests Partially Conserved Neural Substrates for Hind Limb Pain Associated with Distinct Etiologies
LaTasha Crawford, VMD, PhD, University of Wisconsin-Madison, Madison, WI, USA
16.45  **Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv PN) in NEURO-TTRansform, a Phase 3 Study of Eplontersen**  
Marcia Waddington Cruz, MD, National Amyloidosis Referral Center-CEPARM, University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

16.50  **A Mouse Strain with Decreased Scarring Abilities Demonstrates Superior Peripheral Nerve Healing**  
David Milek, University of Rochester, Rochester, NY, USA

16.55  **LXR Synthetic Agonist GW3965 Modifies Neuronal Lipid Homeostasis and Decreases Prostaglandin Production in the Dorsal Root Ganglia of Obese Mice**  
Nadia Elshareif, MS, Loyola University Chicago, Maywood, IL, USA

17.00  **Skin Biopsy in the Clinic**  
Claudia Sommer, MD  
Department of Neurology, University Hospital Würzburg, Würzburg, Germany

**Chairs:**  
Giuseppe Lauria, MD  
IRCCS Fondazione Istituto Neurologico Carlo Besta & University of Milan, Milano, Italy and  
Stephanie Shiers, PhD  
The University of Texas at Dallas, Dallas, TX, USA

17.30  **Platform Presentations**  
**Chairs:** Giuseppe Lauria, MD, IRCCS Fondazione Istituto Neurologico Carlo Besta & University of Milan, Milano, Italy and Stephanie Shiers, PhD, The University of Texas at Dallas, Dallas, TX, USA

17.30  **Lack of Skin Cell-Secreted Neurotrophic Factors Results in a Small Fiber Neuropathy**  
Paula Díaz Cespedes, PhD Candidate, Pontificia Universidad Católica de Chile, Santiago, Chile

17.40  **Neurovascular Interactions in Skin Regeneration: From a Compartmentalized Model to a 3D Tissue-Engineered Skin**  
Amandine Rovini, PhD, INSERM U1026, Université de Limoges, Limoges, France

17.50  **Dysregulated MicroRNA Profile in Skin Epidermis Contributes to Small Fiber Pathophysiology**  
Mirna Andelic, PhD Candidate, Fondazione IRCCS Istituto Neurologico “Carlo Besta” Milano, Italy
PROGRAM – SUNDAY, 15 MAY 2022

18.00 Sensory Neurons Modulate Skin Inflammation
Dan Kaplan, MD, PhD
University of Pittsburgh, PA, USA

Chairs:
Patrik Ernfors, PhD
Karolinska Institutet, Solna, Sweden, and
Cheryl Stucky, PhD
Medical College of Wisconsin, Franklin, WI, USA

18.30 Panel Discussion with all Speakers
Chairs: Dale George, PhD, Postdoc Fellow, Northwestern University, Chicago, IL, USA, and Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA

19.00-19.15 Break
MEZZANINE

19.15-20.15 Sponsored Symposia

CSL Behring Symposium: Use of Immunoglobulin in the Individualized Management of CIDP
TRIANON BALLROOM

19.15 Welcome and Introductions
Amanda Peltier, MD, MS, Vanderbilt University Medical Center, Nashville, TN, USA

19.20 Mechanisms of Action of Intravenous Immunoglobulin in CIDP
Marinos Dalakas, MD, Thomas Jefferson University, Philadelphia, PA, USA

19.35 Will the New 2021 EAN/PNS Guideline Improve CIDP Diagnosis Accuracy?
Mazen Dimachkie, MD, University of Kansas Medical Center, Kansas City, KS, USA

19.50 Treatment of CIDP: How Far Have We Gone?
Jeffrey Allen, MD, University of Minnesota, Minneapolis, MN, USA

20.05 Q&A
Amanda Peltier, MD, MS, Vanderbilt University Medical Center, Nashville, TN, USA

20.10 Close
Amanda Peltier, MD, MS, Vanderbilt University Medical Center, Nashville, TN, USA

IONIS Sponsored Symposium: Mixed Phenotype ATTR Amyloidosis: Are We Seeing the Whole Patient?
VERSAILLES BALLROOM

19.15 Introduction
Sami L. Khella, MD, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

19.20 Neurologist’s Perspective: ATTR Pathophysiology, Diagnosis, and Management
P. James B. Dyck, MD, Mayo Clinic, Rochester, MN, USA
MONDAY, 16 MAY, 2022

19.40  **Cardiologist’s Perspective: ATTR Pathophysiology, Diagnosis, and Management**  
Jose Nativi-Nicolau, MD, Mayo Clinic, Jacksonville, FL, USA

20.00  **Summary and Q&A**  
Sami L. Khella, MD, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

6.45-8.00  Coffee & Exhibits  
6.45-7.45  Sponsored Symposia

**Alnylam Sponsored Symposium: Understanding, Diagnosing, and Treating the Polyneuropathy of hATTR Amyloidosis**  
CHOPIN BALLROOM

Welcome and Introductions  
**Moderator:** George Beran, Alnylam Pharmaceuticals, Cambridge, MA

Overview of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis  
Amanda Peltier, MD, Vanderbilt University Medical Center, Nashville, TN

Review of a Hypothetical Patient Case with the Polyneuropathy of hATTR Amyloidosis  
Amanda Peltier, MD, Vanderbilt University Medical Center, Nashville, TN, and Alejandra González-Duarte, MD, NYU Langone Health, New York, NY

Overview of a Treatment for the Polyneuropathy of hATTR Amyloidosis  
Alejandra González-Duarte, MD, NYU Langone Health, New York, NY

Q&A  
**Moderator:** George Beran, Alnylam Pharmaceuticals, Cambridge, MA  
Alejandra González-Duarte, MD, NYU Langone Health, New York, NY, and Amanda Peltier, MD, Vanderbilt University Medical Center, Nashville, TN

**Grifols Sponsored Symposium: Immunoglobulins in CIDP: Mechanisms of Action and New Genetic Insights**  
GRAND BALLROOM

Chair: Norman Latov, MD, PhD, Weill Cornell Medical College, New York, NY, USA

6.45  Introduction. Program and SPIN Award 2022 Ceremony  
Norman Latov, MD, PhD, Weill Cornell Medical College, New York, NY, USA

6.55  Mechanisms of Action of Immunoglobulin in CIDP  
Marinos Dalakas, MD, FAAN, Thomas Jefferson University, Philadelphia, PA, USA

7.15  Genetic Variations and Clinical Factors Affecting the Response to Immunoglobulin in CIDP  
Krista Kuitwaard, MD, PhD, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

7.35  Q&A and Wrap Up  
Norman Latov, MD, PhD, Weill Cornell Medical College, New York, NY, USA and Faculty
MONDAY, 16 MAY, 2022

8.00-8.30  **Anita Harding Plenary Lecture: The Role of Blood Neural Barriers in Motor Nerve Degeneration**  
GRAND BALLROOM

Charlotte Sumner, MD  
*Johns Hopkins University School of Medicine, Baltimore, MD, USA*

*Chairs:*
Maike Dohrn, MD  
*Hussman Institute for Human Genomics and Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Neurology, Medical Faculty of the RWTH Aachen University Hospital, Aachen, Germany, and Mary Reilly, MD, FRCP, FRCPI, FMedSci  
*University College London, London, United Kingdom*

8.30-9.30  **Platform Session III**  
GRAND BALLROOM

*Chairs: Maike Dohrn, MD, Hussman Institute for Human Genomics and Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Neurology, Medical Faculty of the RWTH Aachen University Hospital, Aachen, Germany, and Mary Reilly, MD, FRCP, FRCPI, FMedSci, University College London, London, United Kingdom*

- **8.30**  
PMP22 Overexpression Causes Lipid Recycling Defects that Alters the Plasma Membrane In CMT1A  
*Robert Prior, PhD Candidate, VIB/KU Leuven, Leuven, Belgium*

- **8.45**  
COVID-19 Vaccination and Guillain-Barré Syndrome: Analyses using the National Immunoglobulin Database  
*Ryan Keh, MRCP, MBBCHIR, MRC Centre for Neuromuscular Diseases, London, United Kingdom*

- **9.00**  
Complement Inhibition Prevents Paranodal Loop Injury in an Anti-GM1 Antibody-Mediated Paranodal Demyelinating Mouse Model  
*Clare Campbell, BSc, University of Glasgow, Glasgow, United Kingdom*

- **9.15**  
Myelinated Human Sensory Neurons Provide a Platform for the Reproducible Screening of Peripheral Nerve-Reactive Autoantibodies in Patient Sera  
*Alexander Davies, PhD, University of Oxford, Oxford, United Kingdom*

8.30-9.30  **Patient Advocacy Group (PAG) Meeting**  
Balmoral

*This is a closed meeting.*
9.30-10.00 Oral Poster Session III  GRAND BALLROOM

**Chairs:** Maike Dohrn, MD, Hussman Institute for Human Genomics and Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Neurology, Medical Faculty of the RWTH Aachen University Hospital, Aachen, Germany, and Mary Reilly, MD, FRCP, FRCPI, FMedSci, University College London, London, United Kingdom

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.30</td>
<td>Targeting Muscle to Rescue Impaired Axonal Transport in Charcot-Marie-Tooth Disease</td>
<td>James Sleigh, DPhil, UCL Institute of Neurology, London, United Kingdom</td>
</tr>
<tr>
<td>9.35</td>
<td>Activation of the UPR Transcription Factors XBP1 and ATF6 Modulates Disease Severity in CMT1B Mice</td>
<td>Maurizio D’Antonio, PhD, San Raffaele Scientific Institute, Milan, Italy</td>
</tr>
<tr>
<td>9.40</td>
<td>WITHDRAWN</td>
<td></td>
</tr>
<tr>
<td>9.45</td>
<td>Normal Aging of the Peripheral Nervous System in the General Population: Clinical and Electrophysiological Characteristics</td>
<td>Noor Taams, MD, Erasmus University Medical Center, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>9.50</td>
<td>Zebrafish In Vivo Imaging of Innate Immune Cell Interactions with Cutaneous Axons in a Paclitaxel Neurotoxicity Model</td>
<td>Antonio Cadiz Diaz, PhD, University of Miami Coral Gables, FL, USA</td>
</tr>
<tr>
<td>9.55</td>
<td>Kinome Dysregulation in a CMT2E iPSC-Derived Motor Neuron System</td>
<td>Jessica Medina, Graduate Student, University of Miami Miller School of Medicine Miami, FL, USA</td>
</tr>
</tbody>
</table>

10.00-10.30 Coffee Break & Exhibits  MEZZANINE

10.00-10.30 IGOS Biobank Meeting  Balmoral

This is an open meeting.

10.30-11.00 Jack Griffin Plenary Lecture: The Schwann Cell-Associated Secretory Phenotype as a Therapeutic Target for Nerve Repair  GRAND BALLROOM

**Felipe A. Court, PhD**
Center for Integrative Biology, Universidad Mayor, Santiago, Chile

**Chairs:**
Marcus Pinto, MD, MS
Mayo Clinic, Rochester, MN, USA, and
John Svaren, PhD
University of Wisconsin-Madison, Madison, WI, USA
MONDAY, 16 MAY, 2022

11.00-11.45  
**Platform Session IV**  
**GRAND BALLROOM**  
**Chairs:** Marcus Pinto, MD, MS, *Mayo Clinic, Rochester, MN, USA,* and John Svaren, PhD, *University of Wisconsin-Madison, Madison, WI, USA*

- **11.00**  
  Programming Injury-Induced Enhancers in Schwann Cells  
  Raghu Ramesh, *University of Wisconsin-Madison, Madison, WI, USA*

- **11.15**  
  PACSIN1-Binding to LRP1, a Pro Survival Receptor in Schwann Cells, Transactivates TrkC via a SRC Family Kinase-Dependent Pathway  
  Stefano Martellucci, PhD, *University of California San Diego, San Diego, CA, USA*

- **11.30**  
  Discovery of Pain-Associated Neuroimmune Protein Interaction Networks from Sex Differential Neuronal and Immune Gene Expression Profiles in Human DRGs  
  Pradipta Ray, PhD, *UT Dallas, Dallas, TX, USA*

11.45-12.00  
**Oral Poster Session IV**  
**GRAND BALLROOM**  
**Chairs:** Marcus Pinto, MD, MS, *Mayo Clinic, Rochester, MN, USA,* and John Svaren, PhD, *University of Wisconsin-Madison, Madison, WI, USA*

- **11.45**  
  A C. Elegans Model of Neuropathy-Associated GARS1 Mutations  
  Jennifer Pierluissi, *University of Michigan, Ann Arbor, MI, USA*

- **11.50**  
  Imaging Calcium Changes in Ex Vivo Mouse Models of Axonal Guillain-Barré Syndrome  
  Madeleine Cunningham, PhD, *University of Glasgow, Glasgow, United Kingdom*

- **11.55**  
  WITHDRAWN

12.00-12.30  
**PNS Annual General Meeting (All Are Welcome)**  
**GRAND BALLROOM**  
All are encouraged to attend the PNS Annual General Meeting as we highlight exciting new Society initiatives. Your input is valuable as we review the business of the PNS.

12.30-14.00  
Lunch & Exhibits  
**MEZZANINE**
### Guided Poster Hall Tour: COVID/Vaccine Neuropathy  
**VERSAILLES BALLROOM**

**Chairs:** Michael Lunn, PhD, National Hospital for Neurology and Neurosurgery Queen Square, London, United Kingdom, and Antonino Uncini, MD, University “G. D’Annunzio” Chieti-Pescara, Italy, Monsampolo del Tronto, Italia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00</td>
<td>Various Peripheral Nerve Complications Associated with COVID-19 Vaccination: A Case Study</td>
<td>David Lauer, MD</td>
<td>Department of Neurology, Third Faculty of Medicine, Charles University, UH Kralovske Vinohrady, Prague, Czech Republic</td>
</tr>
<tr>
<td>13.04</td>
<td>An Inflammatory Lumbar Radiculoplexopathy Pos Severe COVID-19 Infection Associated with Heterotopic Ossification</td>
<td>Camila Pupe, PhD</td>
<td>Universidade Federal Fluminense, Rio de Janeiro/RJ, Brazil</td>
</tr>
<tr>
<td>13.08</td>
<td>Is This An Acute Autonomic Neuropathy Related To COVID Vaccine?</td>
<td>João Marcus de Lima Brito Alves, MD</td>
<td>Universide of São Paulo, Ribeirao Preto, Brazil</td>
</tr>
<tr>
<td>13.12</td>
<td>Peripheral Neuropathy Evaluations of Patients with Long-COVID</td>
<td>Anne Oaklander, MD, PhD</td>
<td>Massachusetts General Hosp, Boston, MA, USA</td>
</tr>
<tr>
<td>13.16</td>
<td>Risk of Recurrences of Guillain-Barré Syndrome or Exacerbations of CIDP and MMN After SARS-CoV-2 Vaccination</td>
<td>Adaja Baars, MD</td>
<td>Erasmus Medical Center, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>13.20</td>
<td>General Discussion (Q&amp;A)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Guided Poster Hall Tour: Stem Cells  
**TRIANON BALLROOM**

**Chairs:** Bruce Conklin, MD, Gladstone Institutes, UCSF, San Francisco, CA, USA, and Mario Saporta, MD, PhD, MBA, University of Miami Miller School of Medicine, Doral, FL, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00</td>
<td>Pre-Clinical Studies in Induced Pluripotent Stem Cell (iPSC) Lines with SORD Mutations Linked to a Recessive Neuropathy</td>
<td>Christopher Yanick</td>
<td>Miami, FL, USA</td>
</tr>
<tr>
<td>13.04</td>
<td>Molecular Characterization of Human Dorsal Root Ganglion Using Spatial RNA Sequencing and RNAscope in Situ Hybridization</td>
<td>Stephanie Shiers, PhD</td>
<td>The University of Texas at Dallas, Richardson, TX, USA</td>
</tr>
<tr>
<td>13.08</td>
<td>IPSC-Derived Motor Neurons Reveal Progressive Mitochondrial Dysfunction in Axonal CMT Subtypes</td>
<td>Jonas Van lent</td>
<td>University of Antwerp, Antwerp, Belgium</td>
</tr>
<tr>
<td>13.12</td>
<td>A hiPS-Derived Cellular Model of Motor Neurons to Investigate Impaired Mechanisms in GDAP1-Associated Charcot-Marie-Tooth Disease</td>
<td>Federica Miressi, PhD</td>
<td>University of Limoges, Limoges, Haute-Vienne, France</td>
</tr>
<tr>
<td>13.16</td>
<td>Severe Congenital Myasthenic Syndromes Caused by AGRIN Mutations Affecting Secretion by Motoneurons</td>
<td>Arnaud Jacquier, PhD</td>
<td>NeuroMyoGene Institut, Lyon, France</td>
</tr>
<tr>
<td>13.20</td>
<td>General Discussion (Q&amp;A)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### MONDAY, 16 MAY, 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00-19.00</td>
<td>SPECIAL INTEREST GROUP (SIG) CONCURRENT SESSIONS – CMTR, IDNC &amp; TNC</td>
<td>VERSAILLES BALLROOM</td>
</tr>
<tr>
<td>14.00-19.00</td>
<td>CHARCOT-MARIE-TOOTH &amp; RELATED NEUROPATHIES CONSORTIUM (CMTR)</td>
<td>VERSAILLES BALLROOM</td>
</tr>
</tbody>
</table>

#### 14.00

**An Update on Treating ATTR Amyloidosis**
Isabel Conceição, MD
CHULN-Hospital de Santa Maria, Faculty of Medicine, Lisbon, Portugal

**Chairs:**
Matilde Laurá, MD, PhD
University College London Hospital, London, United Kingdom, and Pedro Tomaselli, MD, MSc, PhD
Clinical Hospital of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

#### 14.30

**Platform Presentations**

**Chairs:** Matilde Laurá, MD, PhD, University College London Hospital, London, United Kingdom, and Pedro Tomaselli, MD, MSc, PhD, Clinical Hospital of Ribeirão Preto, University of São Paulo, São Paulo, Brazil

- **Skin Amyloid Deposits and Nerve Fiber Loss as Markers of Neuropathy Onset and Progression in Hereditary Transthyretin Amyloidosis**
  Luca Leonardi, Ospedale Sant’Andrea Roma, Roma, Italy

- **Plasma and Skin Biomarkers for Charcot-Marie Tooth Disease**
  John Svaren, PhD, University of Wisconsin-Madison, Madison, WI, USA

#### 15.00

**The Genetics of Pain-Related Neuropathies**
Ingo Kurth, MD
Institute of Human Genetics, Medical Faculty, RWTH Aachen University, Aachen, Germany

**Chairs:**
Jonathan Baets, MD, PhD
Antwerp University Hospital, Antwerp, Belgium, and Andrea Cortese, MD, PhD
Queen Square Centre for Neuromuscular Diseases, London, United Kingdom

#### 15.30

Coffee Break & Exhibits MEZZANINE
MONDAY, 16 MAY, 2022

16.00  Platform Presentations
Chairs: Jonathan Baets, MD, PhD, Antwerp University Hospital, Antwerp, Belgium, and Andrea Cortese, MD, PhD, Queen Square Centre for Neuromuscular Diseases, London, United Kingdom

16.00  A Recurrent Missense Variant in ITPR3 is Associated with Demyelinating CMT
Danique Beijer, PhD, University of Miami, Miami, FL, USA

16.15  Repeat Expansion Size Predicts Age of Onset in RFC1 CANVAS and Disease Spectrum
Riccardo Curro, MD, Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

16.30  Mechanistic Understanding and Therapeutic Discovery for Peripheral Neuropathy using Drosophila Models
Grace Zhai, PhD
University of Miami Miller School of Medicine, Miami, FL, USA

Chairs:
Shawna Feely, MS, LGC
University of Iowa Health Care, Iowa City, IA, USA, and
Mario Saporta, MD, PhD, MBA
University of Miami, Miami, FL, USA

17.00  Platform Presentations
Chairs: Shawna Feely, MS, LGC, University of Iowa Health Care, Iowa City, IA, USA, and Mario Saporta, MD, PhD, MBA, University of Miami, Miami, FL, USA

17.00  Using Machine Learning to Prioritize Rare Repeat Expansions for Pathogenicity
Sarah Fazal, MSc, University of Miami, Miami, FL, USA

17.15  The Role of ATF4 Target-Gene Expression on Neuropathy Phenotype in Mouse Models of Charcot-Marie-Tooth Disease Type 2D
Timothy Hines, PhD, The Jackson Laboratory, Bar Harbor, ME, USA

17.30  Outcome Measures and Biomarkers in CMT for Successful Trial Readiness
David Herrmann, MBBCCh
University of Rochester, Rochester, NY, USA

Chairs:
Alexia Kagiava, PhD, MSc
The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, and
Michael Shy, MD
University of Iowa, Iowa City, IA, USA
18.00 Platform Presentations

**Chairs:** Alexia Kagiava, PhD, MSc, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, and Michael Shy, MD, University of Iowa, Iowa City, IA, USA

18.00 **MAVERICK: Variant Prioritization for Mendelian Diseases Using Deep Learning**

Matt Danzi, PhD, University of Miami, Miami, FL, USA

18.15 **Long-Term Effects of AAV9-MicroRNA-Mediated Gene Silencing in a CMT1A Mouse Model**

Marina Stavrou, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

18.30 Late-Breaking Abstracts

**Chairs:** Vera Fridman, MD, University of Colorado, Englewood, CO, USA, and Marina Kennerson, PhD, ANZAC Research Institute, Conford, Australia

18.30 **Aldose Reductase Inhibitor AT-007 Prevents Mitochondrial Dysfunction And Neurodegeneration in Sorbitol Dehydrogenase Deficiency-Induced Neuropathy**

Yi Zhu, MD, PhD, University of Miami, Miami, FL, USA

18.45 **Structural Variation and Gene-Intergenic Fusions: A Novel Mechanism of Neurodegeneration in Motor Neuron Diseases**

Anthony Cutrupi, PhD, Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia

14.00-19.00 **INTERNATIONAL DIABETES NEUROPATHY CONSORTIUM (IDNC)**

**CHOPIN BALLROOM**

14.00 Welcome

James Russell, MD, MS, CAMC Institute for Academic Medicine, Charleston, WV, USA

14.05 Programmed Axon Death and Human Disease: Pathogenic and Therapeutic Implications in Diabetic Neuropathy

Michael Coleman, PhD

University of Cambridge, Cambridge, United Kingdom

**Chair:**

James Russell, MD, MS

CAMC Institute for Academic Medicine, Charleston, WV, USA
14.50 Platform Presentations

Chair: James Russell, MD, MS, CAMC Institute for Academic Medicine, Charleston, WV, USA

14.50 Plasma Neurofilament Light Chain Concentrations are Elevated in Youth-Onset T2D and Associate with Diabetic Neuropathy
Vera Fridman, MD, University of Colorado, Englewood, CO, USA

15.00 Prevalence and Risk Factor Profiles for Chronic Axonal Polyneuropathy in the General Population
Noor Taams, MD, Erasmus University Medical Center, Rotterdam, Netherlands

15.10 Interactions Between Human Peripheral Sensory Neurons and Immune Cells
Diana Tavares Ferreira, PhD, Plano, TX, USA

15.20 Dietary Interventions in DB/DB Mice Improve Metabolic and Kidney Profiles, but not Peripheral Neuropathy
Stephanie Eid, PhD, University of Michigan, Ann Arbor, MI, USA

15.30 Coffee Break & Exhibits MEZZANINE

16.00 Emerging Biomarkers in Diabetic Neuropathy
Vera Fridman, MD
University of Colorado, Englewood, CO, USA

Chair:
Rodica Pop-Busui, MD, PhD
University of Michigan, Ann Arbor, MI, USA

16.45 Neuroimmune Regulation of Remission and Relapse of Neuropathic Pain
Geoffroy Laumet, PhD, Michigan State University, East Lansing, MI, USA

Chair:
Douglas Wright, PhD, University of Kansas Medical Center, Kansas City, KS, USA
17.30 Inflammation as a Therapeutic Target for Diabetic Peripheral Neuropathy
Rodica Pop-Busui, MD, PhD
University of Michigan, Ann Arbor, MI, USA
Chair: Christopher Gibbons, MD, MMSc
Harvard Medical School, Boston, MA, USA

18.15 Oral Poster Presentations
Chair: Douglas Wright, PhD, University of Kansas Medical Center, Kansas City, KS, USA

18.15 Determining the Prevalence of Distal Symmetric Polyneuropathy in a Low-Income U.S. Patient Population
Melissa Elafros, MD, PhD, University of Michigan, Ann Arbor, MI, USA

18.20 Submicron Topographic Cues Enhance Directionality of Peripheral Nerve Regenerating Fibers
Michele Fornaro, Midwestern University, Downers Grove, IL, USA

18.25 How Often is Peripheral Neuropathy Diagnosed in Patients Referred to an Academic Neuromuscular Clinic?
Benn Smith, MD, Mayo Clinic, Scottsdale, AZ, USA

18.30 Diabetic Lumbosacral Radiculoplexus Neuropathy after COVID-19
Marcus Pinto, MD, MS, Mayo Clinic Rochester, MN, USA

18.35 Ice-Induced Epidermal Denervation: a New Model To Study Degeneration and Regeneration of Skin Nerves
Daniele Cazzato, MD, PhD, IRCCS Foundation “C. Besta” Neurological Institute, Milan, Italy

18.40 The Unmet Need for Disease Modification in Diabetic Peripheral Neuropathy. First Steps: The Taxonomy Project
Roy Freeman, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

18.55 Closing Remarks
James Russell, MD, MS, CAMC Institute for Academic Medicine, Charleston, WV, USA
## MONDAY, 16 MAY, 2022

### 14.00-19.00  
**TOXIC NEUROPATHY CONSORTIUM (TNC)  TRIANON BALLROOM**

#### 14.00  
Emerging Mechanisms of Nerve Damage in CIPN  
**Nathan Staff, MD, PhD**  
*Mayo Clinic, Rochester, MN, USA*

*Chair:*  
**Sandra Rieger, PhD**  
*University of Miami, Coral Gables, FL, USA*

#### 14.30  
Different Approaches to CIPN Assessment: Serum Biomarkers  
**Paola Alberti, MD, PhD**  
*University of Milano-Bicocca, Monza, Italy*

Apps and Wearables for Remote CIPN Monitoring  
**Nathan Daniel Hertz, PharmD, PhD**  
*University of Michigan, Ann Arbor, MI, USA*

*Discussant:*  
**Maryam Lustberg, MD, MPH**  
*Yale Cancer Center, New Haven, CT, USA*

*Chair:*  
**Chiara Briani, MD**  
*University of Padova, Padova, Italy*

#### 15.10  
General Discussion

#### 15.30  
Coffee Break & Exhibits  
**MEZZANINE**

#### 16.00  
Update on TNC Activities  
**Guido Cavaletti, MD**  
*University of Milano-Bicocca, Milan, Italy*

#### 16.30  
Platform Presentations  
*Chair: Andreas Argyriou, MD, PhD*  
*Saint Andrew’s State General Hospital of Patras; Neurology Dept., Patras, Greece*

**16.30**  
Neuron-Macrophage Interactions in Models of Chemotherapy-Induced Peripheral Neuropathy  
**Grace Shin, PhD**  
*Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA*

**16.45**  
Characterization of Axonal Degeneration Mechanisms in Bortezomib-Treated Sensory Neurons  
**Laura Monza, PhD**  
*Experimental Neurology Unit, School of Medicine and Surgery, Monza, Italy*
17.00  Netazepide is Neuroprotective in a Mouse Model of Vincristine-Induced Sensory Neuropathy  
Amandine Bernard, PhD Student, EA6309, Limoges, France

17.15  Neuroprotective Effect of hlg in Mouse Models of Chemotherapy-Induced Neuropathy  
Aurore Danigo, PhD, EA6309_MMNP, Faculté de Médecine et de Pharmacie Limoges, Cedex, France

17.30  Morpho-Functional Characterization of the Caudal Nerve to Refine Assessment of Peripheral Neuropathy in Rat Models  
Paola Alberti, MD, PhD, University of Milano-Bicocca, Monza, Italy

17.45  Functional Characterisation of Missense Variants in the Pro-Survival Gene NMNAT2  
Mirlinda Ademi, MD, University of Cambridge, Cambridge, United Kingdom

18.00  Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neuropathy  
Fawaz Mahfouz, BAdvSc (Hons), The University of Sydney, Camperdown, Australia

18.15  Bortezomib Neuropathy: Characteristics of a Cohort from a Tertiary Multiple Myeloma Treatment Center  
Daniel Schirmer, cand. med., Universitätsklinikum Würzburg, Würzburg, Germany

18.30  A Study of Endemic Sensory, Optic and Auditory Neuropathy in the UK Black Caribbean Community  
Caroline Kramarz, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, United Kingdom

18.45  Information and Communication Technology Devices and Applications for Chemotherapy-Induced Peripheral Neurotoxicity: a Systematic Review  
Stefano Tamburin, MD, PhD, University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Verona, Italy

15.30-16.00  JPNS Editorial Board Meeting  BALMORAL
This is a closed meeting.

19.00-19.15  Break  MEZZANINE

19.15-20.15  Sponsored Symposia
Pfizer Sponsored Symposium: An Intravenous Immunoglobulin Treatment With 2 FDA-Approved Maintenance Dosing Options for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

**TRIANON BALLROOM**

**Speaker:** Sami Khella, MD, **Professor of Clinical Neurology, University of Pennsylvania School of Medicine, and Chief, Department of Neurology, Penn Presbyterian Medical Center, Pennsylvania, PA, USA**

Takeda Sponsored Symposium: A Practical Approach to Diagnosis and Management of MMN: Past, Present and Future

**VERSAILLES BALLROOM**

19.15  **Welcome, Introductions and Objectives**
*Jeffrey Allen, MD, University of Minnesota, Minneapolis, MN, USA*

19.18  **What is MMN? Disease Overview and Pathophysiology**
*Norman Latov, MD, PhD, Weill Cornell Medicine, New York, NY, USA*

19.33  **What is the Future for Diagnosing MMN? Overcoming Challenges in Current Diagnostic Approaches for MMN**
*Mamantha Pasnoor, MD, The University of Kansas Medical Center, Kansas City, KS, USA*

19.48  **What are the Unmet Needs for Patients with MMN? Following the Patient Journey**
*Jeffrey Allen, MD, University of Minnesota, Minneapolis, MN, USA*

20.03  **Q&A Session**
*All Faculty*

20.15  **Meeting Close**

20.15-21.15  **International Diabetes Neuropathy Consortium (IDNC) Board Meeting**
*This is a closed meeting.*
## PROGRAM – TUESDAY, 17 MAY 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.45-8.00</td>
<td>Coffee &amp; Exhibits MEZZANINE</td>
</tr>
<tr>
<td>6.45-8.00</td>
<td>Poster Viewing BISCAYNE BALLROOM</td>
</tr>
<tr>
<td>8.00-8.30</td>
<td>PK Thomas Plenary Lecture: Gene Therapies for Inherited Demyelinating Neuropathies GRAND BALLROOM</td>
</tr>
<tr>
<td></td>
<td>Kleopas Kleopa, MD, FAAN</td>
</tr>
<tr>
<td></td>
<td>The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong></td>
</tr>
<tr>
<td></td>
<td>Kathryn Moss, PhD</td>
</tr>
<tr>
<td></td>
<td>Johns Hopkins University, Baltimore, MD, USA, and</td>
</tr>
<tr>
<td></td>
<td>Steven Scherer, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>The University of Pennsylvania, Media, PA, USA</td>
</tr>
<tr>
<td>8.30-9.30</td>
<td>Platform Session V GRAND BALLROOM</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Kathyrn Moss, PhD, Johns Hopkins University, Baltimore, MD, USA, and</td>
</tr>
<tr>
<td></td>
<td>Steven Scherer, MD, PhD, The University of Pennsylvania, Media, PA, USA</td>
</tr>
<tr>
<td>8.30</td>
<td>Preclinical Evaluation of CLZ-2002, Neuronal Regeneration Promoting Cells in a CMT IA Mouse Model</td>
</tr>
<tr>
<td></td>
<td>Sung-Chul Jung, Professor, Ewha Womans University College of Medicine, Seoul, Republic of Korea</td>
</tr>
<tr>
<td>8.45</td>
<td>Clustering Peripheral Neuropathy Models with Transcriptomic Data to Identify Shared Pathways, Predictive Signatures, and Therapeutic Targets</td>
</tr>
<tr>
<td></td>
<td>George Murray, The Jackson Laboratory / The University of Maine, Bar Harbor, ME, USA</td>
</tr>
<tr>
<td>9.00</td>
<td>Development of ORT247, a Monoclonal Antibody Antagonist of EphA4, for the Treatment of CMT and ALS</td>
</tr>
<tr>
<td></td>
<td>Michael Ahlijanian, PhD, Orthogonal Neuroscience, Newton Centre, MA, USA</td>
</tr>
<tr>
<td>9.15</td>
<td>A Role for Calpain in Secondary Loss of Axonal Integrity in Experimental Models of Paranodal Demyelination</td>
</tr>
<tr>
<td></td>
<td>Rhona McGonigal, PhD, University of Glasgow, Glasgow, United Kingdom</td>
</tr>
<tr>
<td>9.30-10.00</td>
<td>Oral Poster Session V GRAND BALLROOM</td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Kathyrn Moss, PhD, Johns Hopkins University, Baltimore, MD, USA, and</td>
</tr>
<tr>
<td></td>
<td>Steven Scherer, MD, PhD, The University of Pennsylvania, Media, PA, USA</td>
</tr>
<tr>
<td>9.30</td>
<td>Allele-Specific Inactivation of Dominant CMT2E Mutations via CRISPR Targeting Common Polymorphisms</td>
</tr>
<tr>
<td></td>
<td>Luke Judge, MD, PhD, Gladstone Institutes, San Francisco, CA, USA</td>
</tr>
</tbody>
</table>
9.35  The First Two Large Deletions of KIF5A Responsible for Charcot-Marie-Tooth Disease, Detected Using CovCopCan Software
Ioanna Pyromali, Université de Limoges, Limoges, France

9.40  Biallelic Variants in COQ7 Leading to Coenzyme Q10 Deficiency Cause Charcot-Marie-Tooth Disease
Adriana Rebelo, PhD, University of Miami, Miami, FL, USA

9.45  Neurodegeneration in HSAN1 due to ATL1 (Gly66Gln) Mutation is Associated with Defective ER- Protein Quality Control and Compromised Autophagy
Istvan Katona, MD, RWTH Aachen University, Insitute of Neuropathology, Aachen, Germany

9.50  Update on the International Guillain-Barré syndrome Outcome Study (IGOS)
Robin Thomma, MD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

9.55  A Model For Therapeutic Screening Of Chemotherapy-Induced Peripheral Neuropathy Using A Nerve-on-a-Chip Microphysiological System
J. Curley, PhD, AxoSim, Inc., New Orleans, LA, USA

10.00-10.30  Coffee Break & Exhibits MEZZANINE

10.00-10.30  TNC Board Meeting BALMORAL (2ND FLOOR)
This is a closed meeting.

10.30-11.00  Jonathan Pembroke Plenary Lecture: Transduction of Light Touch and Mechanical Pain by Sensory Schwann Cells GRAND BALLROOM

Patrik Ernfors, PhD
Karolinska Institutet, Solna, Sweden

Chairs:
Daniela Maria Menichella, MD, PhD
Northwestern University, Chicago, IL, USA, and
Grace Shin, PhD
Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

11.00-11.45  Platform Session VI GRAND BALLROOM
Chairs: Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA, and Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

11.00  Targeting the Sigma 2 Receptor/TMEM97 to Treat Neuropathic Pain
Muhammad Saad Yousuf, PhD, University of Texas at Dallas, Richardson, TX, USA
## PROGRAM – TUESDAY, 17 MAY 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.15</td>
<td>Activation of Keratinocyte Gq-linked G-Protein Coupled Receptors Remodels Dorsal Root Ganglion Neurons Single-Cell Transcriptomic Profile</td>
<td>GRAND BALLROOM</td>
</tr>
<tr>
<td></td>
<td><strong>Abdelhak Belmadani, PhD</strong>, Northwestern University Feinberg School of Medicine, Chicago, IL, USA</td>
<td><strong>Abdelhak Belmadani, PhD</strong>, Northwestern University Feinberg School of Medicine, Chicago, IL, USA</td>
</tr>
<tr>
<td>11.30</td>
<td>Persistence of Intact Sensory Afferents and Myelin Thinning Correlates with Long-Term Hypersensitivity after Partial Crush of the Peripheral Nerve</td>
<td>GRAND BALLROOM</td>
</tr>
<tr>
<td></td>
<td><strong>Alexander Davies, PhD</strong>, University of Oxford, Oxford, United Kingdom</td>
<td><strong>Alexander Davies, PhD</strong>, University of Oxford, Oxford, United Kingdom</td>
</tr>
<tr>
<td>11.45-12.00</td>
<td>Oral Poster Session VI <strong>GRAND BALLROOM</strong></td>
<td><strong>GRAND BALLROOM</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA, and Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA</td>
<td><strong>Chairs:</strong> Daniela Maria Menichella, MD, PhD, Northwestern University, Chicago, IL, USA, and Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA</td>
</tr>
<tr>
<td>11.45</td>
<td>Changes in the Expression of TRP Channels Induced by Oxaliplatin in Lumbar Dorsal Root Ganglia and Spinal Cord of Male and Female Rats</td>
<td>GRAND BALLROOM</td>
</tr>
<tr>
<td></td>
<td><strong>Constanza Miguel, PhD Candidate</strong>, Instituto de Investigaciones en Medicina Traslacional-Conicet-Universidad Austral, Pilar, Argentina</td>
<td><strong>Constanza Miguel, PhD Candidate</strong>, Instituto de Investigaciones en Medicina Traslacional-Conicet-Universidad Austral, Pilar, Argentina</td>
</tr>
<tr>
<td>11.50</td>
<td>TRPA1 Rare Variants in Chronic Neuropathic Pain Patients</td>
<td>GRAND BALLROOM</td>
</tr>
<tr>
<td></td>
<td><strong>Margherita Marchi, MSc</strong>, IRCCS Istituto Neurologico C. Besta, Milano, Italy</td>
<td><strong>Margherita Marchi, MSc</strong>, IRCCS Istituto Neurologico C. Besta, Milano, Italy</td>
</tr>
<tr>
<td>11.55</td>
<td>Nerve Regeneration Following Ablation of Monocarboxylate Transporters 1, 2 and 4 from Schwann Cells</td>
<td>GRAND BALLROOM</td>
</tr>
<tr>
<td></td>
<td><strong>Joseph Passero</strong>, John Hopkins University School of Medicine, Baltimore, MD, USA</td>
<td><strong>Joseph Passero</strong>, John Hopkins University School of Medicine, Baltimore, MD, USA</td>
</tr>
<tr>
<td>12.00-14.00</td>
<td>Lunch &amp; Exhibits <strong>MEZZANINE</strong></td>
<td><strong>MEZZANINE</strong></td>
</tr>
<tr>
<td>12.00-14.00</td>
<td><strong>Poster Session II</strong> <strong>BISCAYNE BALLROOM</strong></td>
<td><strong>BISCAYNE BALLROOM</strong></td>
</tr>
<tr>
<td>13.00-13.30</td>
<td>Guided Poster Hall Tour: Fluid Biomarkers <strong>VERSAILLES BALLROOM</strong></td>
<td><strong>VERSAILLES BALLROOM</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Krista Kuitwaard, MD, PhD, Erasmus MC, Rotterdam, Netherlands, and Alexander Rossor, FRCP, PhD, UCL, London, United Kingdom</td>
<td><strong>Chairs:</strong> Krista Kuitwaard, MD, PhD, Erasmus MC, Rotterdam, Netherlands, and Alexander Rossor, FRCP, PhD, UCL, London, United Kingdom</td>
</tr>
<tr>
<td>13.00</td>
<td>Serum Neurofilament Light Chain Associated with Outcome in Guillain-Barré Syndrome Across Regional and Disease Spectrums</td>
<td>VERSAILLES BALLROOM</td>
</tr>
<tr>
<td></td>
<td><strong>Henk-Andre Kroon, MD, MBA</strong>, Annexon Biosciences, Brisbane, CA, USA</td>
<td><strong>Henk-Andre Kroon, MD, MBA</strong>, Annexon Biosciences, Brisbane, CA, USA</td>
</tr>
<tr>
<td>13.04</td>
<td>Longitudinal Serum Neurofilament Light Chain Levels as Biomarker of Axonal Injury in Guillain-Barré Syndrome</td>
<td>VERSAILLES BALLROOM</td>
</tr>
<tr>
<td></td>
<td><strong>Sander van Tilburg, Drs</strong>, Erasmus MC, Rotterdam, Netherlands</td>
<td><strong>Sander van Tilburg, Drs</strong>, Erasmus MC, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>13.08</td>
<td>Biomarkers Associated with Disease Severity and Outcome in Guillain-Barré Syndrome: a Prospective Cohort Study</td>
<td>VERSAILLES BALLROOM</td>
</tr>
<tr>
<td></td>
<td><strong>Israt Jahan, MS</strong>, Laboratory of Gut-Brain Signaling, Laboratory Sciences and Services Division, icddr,b, Dhaka, Bangladesh</td>
<td><strong>Israt Jahan, MS</strong>, Laboratory of Gut-Brain Signaling, Laboratory Sciences and Services Division, icddr,b, Dhaka, Bangladesh</td>
</tr>
</tbody>
</table>
## PROGRAM – TUESDAY, 17 MAY 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.12</td>
<td>NCAM1 and GDF15 are Biomarkers of Charcot-Marie-Tooth Disease in Patients and Mice</td>
</tr>
<tr>
<td></td>
<td>Matthew Jennings, PhD, Cambridge University, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>13.16</td>
<td>Utility of Plasma Neurofilament Light Chain in Determining Subclinical Disease Activity in Chronic Inflammatory Demyelinating Polyradiculoneuropathy</td>
</tr>
<tr>
<td></td>
<td>Mahima Kapoor, MBBS, FRACP, Alfred Hospital, Monash University Prahran, Victoria, Australia</td>
</tr>
<tr>
<td>13.20</td>
<td>General Discussion (Q&amp;A)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13.00-13.30</th>
<th>Guided Poster Hall Tour: Trials &amp; Therapies</th>
<th>TRIANON BALLROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairs:</td>
<td>Teresa Coelho, MD, Hospital de Santo Antonio, Porto, Portugal, and Filip Eftimov, MD, PhD, University of Amsterdam, Amsterdam, Netherlands</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00</td>
<td>AT-007 Significantly Lowers Blood Sorbitol Levels in Patients with Hereditary Neuropathy Resulting from Sorbitol Dehydrogenase (SORD) Deficiency</td>
</tr>
<tr>
<td></td>
<td>Riccardo Perfetti, MD, PhD, Applied Therapeutics, New York, NY, USA</td>
</tr>
<tr>
<td>13.04</td>
<td>Allografts in Combination with Local Immune Suppression as a Strategy to Improve Peripheral Nerve Regeneration</td>
</tr>
<tr>
<td></td>
<td>JuliAnne Allgood, University of Wyoming, Laramie, WY, USA</td>
</tr>
<tr>
<td>13.08</td>
<td>Assessment Timing and Choice of Outcome Measure in Determining Treatment Response in CIDP: a Post-Hoc Analysis of the PRISM Trial</td>
</tr>
<tr>
<td></td>
<td>Rabye Ouaja, Dr, LFB, Les Ulis, France</td>
</tr>
<tr>
<td>13.12</td>
<td>Population Pharmacokinetic Modeling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome</td>
</tr>
<tr>
<td></td>
<td>Sander van Tilburg, Drs, Erasmus MC, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>13.16</td>
<td>Real-World Experience with Inotersen at Ceparm University Hospital</td>
</tr>
<tr>
<td></td>
<td>Marcia Cruz, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil</td>
</tr>
<tr>
<td>13.20</td>
<td>General Discussion (Q&amp;A)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14.00-16.00</th>
<th>Basic Science Highlights</th>
<th>VERSAILLES BALLROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00-14.40</td>
<td>Part I: Neuro-Immune Crosstalk: Cellular Interactions and Novel Pathways</td>
<td>Chair: Ruth Huizinga, PhD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>14.00</td>
<td>Introduction</td>
<td>Ruth Huizinga, PhD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands</td>
</tr>
<tr>
<td>14.06</td>
<td>Neuron-Macrophage Interactions in Models of Chemotherapy-Induced Peripheral Neuropathy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA</td>
<td></td>
</tr>
</tbody>
</table>
14.12 Interactions Between Human Peripheral Sensory Neurons and Immune Cells
Diana Tavares Ferreira, PhD, Plano, TX, USA

14.18 Discovery of Pain-Associated Neuroimmune Protein Interaction Networks from Sex Differential Neuronal and Immune Gene Expression Profiles in Human DRGs
Pradipta Ray, PhD, UT Dallas, Dallas, TX, USA

14.24 Downregulation of Leukocyte LKB1/AMPK Signaling is Associated with the Severity of Guillain-Barre Syndrome Independently of Autophagy
Ivo Bozovic, Belgrade, Serbia

14.30 Q&A with all Speakers
Ruth Huizinga, PhD, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

14.40-15.20 Part II: Injury Responses in Neurons and Glia
Chair: Elisabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA

14.40 Introduction
Elisabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA

14.45 Injury, Degeneration, and Regeneration
Speakers:
Courtney Hatton, The Jackson Laboratory, Old Town, ME, USA
Stefano Martellucci, PhD, University of California San Diego, San Diego, CA, USA
Juliet Mwirigi, BS, Richardson, TX, USA
Joseph Passero, John Hopkins University School of Medicine, Baltimore, MD, USA
Raghu Ramesh, University of Wisconsin-Madison, Madison, WI, USA

14.55 Cell-Cell Interaction in Injury and Disease
Speakers:
Melissa Heredia, MS, University of California San Diego, La Jolla, CA, USA
James Sleigh, DPhil, UCL Institute of Neurology, London, United Kingdom

15.05 Q&A with all Speakers
Elisabetta Babetto, PhD, SUNY at Buffalo, Buffalo, NY, USA
15.20-16.00 Part III: Peripheral Mechanisms of Neuropathic Pain
Chair: Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

15.20 Introduction
Grace Shin, PhD, Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, USA

15.30 Panel Discussion
Speakers:
Paula Diaz Cespedes, PhD(c), Pontificia Universidad Católica de Chile, Santiago, Chile
Patrik Ernfors, PhD, Karolinska Institutet, Solna, Sweden
Dale George, PhD, Postdoc Fellow, Northwestern University, Chicago, IL, USA

14.00-16.00 Richard A.C. Hughes Symposium: Clinical Highlights
TRIANON BALLROOM
Chairs: Mary Reilly, MD, FRCP, FRCPI, FMedSci, University College London, London, United Kingdom, and David Cornblath, MD, Johns Hopkins University, Baltimore, MD, USA

14.00 Natural History Study of Sord Neuropathy
Andrea Cortese, MD, PhD, Queen Square Centre for Neuromuscular Diseases, London, United Kingdom

14.10 MRI Measured Dixon Fat Fraction is a Responsive Outcome Measure in CMT1X, CMT1B, and CMT2A
Carolynne Doherty, MD, Queen Square Centre for Neuromuscular Diseases, London, United Kingdom

14.20 Predictors of Mobility, Balance, and Lower Extremity Function in Adult Charcot-Marie-Tooth Disease Type 1
Timothy Estilow, OT, The Children’s Hospital of Philadelphia & University of Philadelphia, Philadelphia, PA, USA

14.30 Neuropathy Progression in ATTRv Patients after Orthotopic Liver Transplant
Catarina Falcao de Campos, Hospital Santa Marta, Lisbon, Portugal

14.40 WITHDRAWN

14.50 HELIOS-A: Impact of Vutrisiran on Quality of Life and Functional Status in Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Senda Ajroud-Driss, MD, Northwestern University, Chicago, IL, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.00</td>
<td>Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN): a NeuroNEXT Trial</td>
<td>Gordon Smith, MD, VCU, Richmond, Virginia, USA</td>
<td></td>
</tr>
<tr>
<td>15.10</td>
<td>A Double-Blind, Placebo Controlled Trial of IVIG in Patient with Small Fiber Neuropathy Associated with Autoantibodies to TS-HDS and FGFR3</td>
<td>Christopher Gibbons, MD, MMSc, Harvard Medical School, Boston, MA, USA</td>
<td></td>
</tr>
<tr>
<td>15.20</td>
<td>Rozanolixizumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Randomized Subject-/Investigator-Blind Placebo-Controlled Phase 2a Trial</td>
<td>Luis Querol, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>15.30</td>
<td>OPTIC Trial: Intravenous Immunoglobulin and Intravenous Methylprednisolone as Induction Treatment in CIDP – Study Update</td>
<td>Iris van Doorn, MD, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, Netherlands</td>
<td></td>
</tr>
<tr>
<td>15.40</td>
<td>Italian Database on Multifocal Motor Neuropathy: Lesson from the First 100 Included Patients</td>
<td>Eduardo Nobile-Orazio, MD, PhD, Milan University, IRCCS Humanitas Research Institute Rozzano, Milan, Lombardia, Italy</td>
<td></td>
</tr>
<tr>
<td>15.50</td>
<td>Target Therapies: Towards a Tailored Therapy in Anti-MAG Antibody Neuropathy with Ibrutinib, Venetoclax, and Obinutuzumab</td>
<td>Francesca Castellani, MD, Department of Neurosciences, Neurology Padova, Padova, Italy</td>
<td></td>
</tr>
</tbody>
</table>

16.00-16.30 Coffee Break & Exhibits   MEZZANINE

16.00-16.30 PNS Prize Committee Meeting   GROVE (1ST FLOOR)
This is a closed meeting.

16.00-16.30 PNS Annual Partners Roundtable Meeting   BALMORAL
This is a closed meeting.

16.30-17.00 Arthur K. Asbury/Presidential Plenary Lecture: Improve the Lives of People with Peripheral Neuropathies   GRAND BALLROOM

Pieter van Doorn, MD, PhD
Erasmus MC University Medical Center, Rotterdam, Netherlands

Chairs:
Rich Lewis, MD
Cedars-Sinai, Los Angeles, CA, USA, and
Luuk Wieske, MD, PhD
Amsterdam University Medical Centers, Amsterdam, Netherlands
PROGRAM – TUESDAY, 17 MAY 2022

17.00-17.30  
**Awards Ceremony** GRAND BALLROOM  
*Master of Ceremonies: Rich Lewis, MD, Cedars-Sinai, Los Angeles, CA, USA*  
Please join us as we honor one of our esteemed PNS colleagues with the presentation of the prestigious Alan J. Gebhart Prize for Excellence in Peripheral Nerve Research. We will also present several $750 cash prizes to Junior Member abstract presenters at the awards ceremony. Being chosen as a prize winner is considered an honor and commemorates the contributions of previous leaders in the industry.

17.30-18.30  
**Neuropathic Pain Consortium (NPC) Board Meeting** BALMORAL  
*This is a closed meeting.*

19.00-22.00  
**Closing Reception** INTERCONTINENTAL MIAMI SKYLAWN – POOL DECK (5TH FLOOR)  
Located on the 5th-floor pool deck, the hotel's SkyLawn overlooks the Miami skyline. Join us for a private reception with live music, dancing, and more. The PNS has reserved the entire rooftop area for the Closing Reception. Appetizers and drinks will be provided.

PROGRAM – WEDNESDAY, 18 MAY 2022

07.30-08.30  
**Charcot-Marie-Tooth & Related Neuropathies (CMTR) Board Meeting** ESCORIAL  
*This is a closed meeting.*

07.30-08.30  
**Inflammatory Neuropathy Consortium (INC) Board Meeting** RAPHAEL/MICHELANGELO  
*This is a closed meeting.*

09.00-12.00  
**Peripheral Nerve Society (PNS) Board Meeting** RAPHAEL/MICHELANGELO  
*This is a closed meeting.*
Exhibitors
EXHIBITOR MAP

INTERCONTINENTAL HOTEL
MEZZANINE LEVEL 2

ATRIUM

1. Neurocode Labs
2. Grifols
3. IONIS
4. Janssen
5. Sanofi
6. CSL Behring Medical Booth
7. Takeda
8. KabaFusion
9. Muscular Dystrophy Association
10. CMT Research Foundation
11. Hunters CMT4B3 Research Foundation
12. Hereditary Neuropathy Foundation
13. Charcot-Marie-Tooth Association (CMTA)
14. GBS|CIDP Foundation International
15. The Foundation for Peripheral Neuropathy
16. Alnylam
17. Pharnext
18. Octapharm AG
19. Applied Therapeutics
20. Pfizer
21. Takeda
22. CSL Behring
23. CSL Behring
24. CSL Behring
25. Alnylam Pharmaceuticals – Medical
26. argenx
27. Variantyx
28. AxoSim
29. European CMT Federation

2022 Annual Meeting
14-17 May, Miami, Florida
Alnylam Pharmaceuticals
– Medical
BOOTH #1
www.alnylam.com
medinfo@alnylam.com

About Alnylam Pharmaceuticals
Headquartered in Cambridge, MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. For more information visit www.alnylam.com.

IONIS
BOOTH #3
www.ionispharma.com
medinfo@ionisph.com

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. To learn more, visit www.ionispharma.com.

GRIFOLS
BOOTH #2
www.grifols.com/en/home
immunologyneurology@grifols.com

Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Our four divisions — Bioscience, Diagnostic, Hospital and Bio Supplies — develop, produce and market innovative medicines, solutions and services in more than 100 countries.

Janssen Pharmaceuticals
BOOTH #4
www.janssen.com
www.twitter.com/JanssenGlobal

At Janssen, we’re creating a future where disease is a thing of the past — including rare diseases, which affect 300 million people around the globe. That’s why we’re investigating new approaches to the treatment of rare neurological diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP). Follow us at www.twitter.com/JanssenGlobal for updates.
Sanofi

BOOTH #5

med.info@sanofi.com

Sanofi’s Specialty Care business is committed to meeting significant unmet medical needs. With a well-established heritage in multiple sclerosis, we continue to forge the way in neurology, seeking to provide hope where none existed before, developing innovative approaches to treatments based on patient insights, scientific expertise, and cutting-edge technology. By partnering with scientific, healthcare and patient communities, we continue to build on our legacy of collaboration and inspiration, understanding and experience, empathy and knowledge to drive the development of potential new therapies and to help change what it means to live with a neurological disease. Learn more about these partnerships and possibilities at https://www.sanofi.com/en/your-health/specialty-care MAT-US-2100661

Takeda – Commercial Booth

BOOTH #7

www.takeda.com
US.corporatecommunications@takeda.com

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. www.takeda.com

KabaFusion

BOOTH #8

www.KabaFusion.com
LSerpa@KabaFusion.com

KabaFusion is a patient-focused, pharmacist-owned, home infusion provider. We are dedicated to working proactively with our patients, healthcare practitioners and payors to provide comprehensive support before, during, and after treatment. KabaFusion has years of experience providing home infusions and is recognize for excellence in the administration of Intravenous Immune Globulin (IVIG) nationwide. If you would like to refer your next IVIG patient to KabaFusion, please contact us by phone or fill out our online IVIG referral form at: www.KabaFusion.com

CSL Behring

Biotherapies for Life™

CSL Behring Medical Affairs

BOOTH #6

www.cslbehring.com
www.cslbehring.com/contact

CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people in more than 100 countries living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
European CMT Federation

www.ecmtf.org
secretary@ecmtf.org

The European CMT Federation (ECMTF) is a non-profit organization grouping European national associations supporting people affected by the Charcot-Marie-Tooth disease. One of our primary goals is to encourage research projects for an affordable and effective treatment, and to raise awareness on CMT. We believe in cooperation. Together we are stronger.

Muscular Dystrophy Association

www.mda.org
ResourceCenter@mdausa.org

MDA is the largest source of funding for neuromuscular research outside of the federal government. We are working aggressively to advance therapy development through support of innovative research in universities and industry and through collection of healthcare data in the MOVR Data Hub. Since our inception in the 1950’s we have invested over $1B in R&D and 8 drugs have come to market partly through our sponsorship and support. We also maintain a network of over 150 care centers across the United States, providing care for 60,000 patients living with muscular dystrophy, ALS and other neuromuscular diseases annually, to give access to expert multidisciplinary care, clinical trials, and engage with MDA and the neuromuscular community.

CMT Research Foundation

www.cmtrf.org
info@cmtrf.org

The mission of the CMT Research Foundation is to deliver treatments and cures for CMT during our lifetime. Founded by two patients who are driven to expedite drug delivery to people who live with CMT globally, the organization supports research focused on the discovery and development of therapeutics. The CMT Research Foundation pursues this goal by identifying and bridging gaps in biomedical research, with a focus on areas that are most likely to result in treatments. We are most focused on translational research, but also fund discovery phase research with a clear link to speeding progress toward treatments and cures. The CMT Research Foundation accepts proposals that address four key scientific barriers to drug development: delivering therapies to the peripheral nervous system, advancing genetic medicine, promoting nerve health, and de-risking clinical trials.
Hunters CMT4B3 Research Foundation

www.cmt4b3research.org
info@cmt4b3research.org

Hunters CMT4B3 Research Foundation, was founded to fund, support and advance research including the development and production of therapeutic treatments for Charcot-Marie-Tooth Disease Type 4B3 (CMT4B3) and other related inherited neuromuscular disorders. The mission of the foundation is to improve public awareness of CMT, advance education, develop gene therapies, novel drug discovery and drug repurposing treatments, as well as implement a patient registry for CMT4B3 to improve the quality of life of those suffering from this disorder.

Hereditary Neuropathy Foundation (HNF)

www.hnf-cure.org
info@hnf-cure.org

HNF held the monumental FDA EI-PFDD meeting. HNF funds impactful research with dozens of academic/industry collaborations, including biotech seed funding. HNF is patient powered, patient centered and patient driven! HNFs Inspire® Support Community, the patient registry, GRIN, and the AI Powered CMT Mobile App are at the core mission.

Charcot-Marie-Tooth Association (CMTA)

www.cmtausa.org
Info@cmtausa.org

Founded by patients in 1983, the vision of the CMTA has always been a “A World Without CMT” and we will accomplish this mission by accelerating research and empowering patients. We are devoted to: 1. Driving the development of new drugs to treat CMT 2. Meeting the needs of patients with CMT 3. Accelerating research for a cure Leading us in our mission is the governing CMTA Board of Directors and a STAR Advisory Board comprised of the world’s foremost CMT research scientists, clinicians and experts in the field of developing pharmacological therapeutics. The CMTA has an incredible community of patients, families, and supportive friends — along with hundreds of experts in neurology, genetics, orthopedic surgery, physiatry, physical therapy and podiatry — all committed to our vision.

GBS|CIDP Foundation International

gbs-cidp.org
info@gbs-cidp.org

The GBS/CIDP Foundation International is the preeminent global non-profit organization supporting individuals and their families affected by Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and related syndromes such as multifocal motor neuropathy (MMN) through a commitment to support, education, research and advocacy.
The Foundation for Peripheral Neuropathy

The Foundation for Peripheral Neuropathy aims to improve the lives of patients living with PN. We do so by funding research grants, lobbying for more research dollars through the DOD and the NIH, raising awareness of PN, providing educational resources to patients, and funding the PN Research Registry, FPN’s very own unique biobank of DNA samples from over 2,000 patients for researchers to access.

Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals Headquartered in Cambridge, MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. For more information visit www.alnylam.com.

Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships.

Octapharma AG

Octapharma is one of the world’s largest human protein manufacturers, developing and producing human proteins from human plasma and human cell lines. We employ around 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology, and Critical Care.
EXHIBITOR DIRECTORY

APPLIED THERAPEUTICS

**Applied Therapeutics**
**BOOTH #20**

www.appliedtherapeutics.com
info@appliedtherapeutics.com

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, such as Sorbitol Dehydrogenase (SORD) Deficiency. When someone is living with a debilitating disease for which no drugs are available, everyday counts.

Takeda – Medical Booth
**BOOTH #22**

www.takeda.com
US.corporatecommunications@takeda.com

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. www.takeda.com

Pfizer, Inc.
**BOOTH #21**

www.pfizer.com

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

CSL Behring
**BOOTH #23**

www.cslbehring.com
www.cslbehring.com/contact

CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people in more than 100 countries living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
Neurocode Lab

BOOTH #25

www.neurocode.com
info@neurocode.com

A CAP/CLIA accredited clinical laboratory located in Bellingham Washington. Seeking excellence in neuroimmunology and neurodegeneration testing. As the first USA based clinical laboratory, offers best in class cell-based testing for CIDP and Myasthenia Gravis.

Variantyx

BOOTH #27

variantyx.com
info@variantyx.com

Variantyx uses a unique whole genome platform to identify all major genetic changes from a single patient sample. The Genomic Unity® test portfolio has industry-leading sensitivity and specificity, with easy reflex options to comprehensive analyses. Together, we can rapidly end the diagnostic search, inform management, and optimize treatment.

argenx

BOOTH #26

www.argenx.com
medinfo@argenx.com

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases by translating immunology breakthroughs into potential new medicines. argenx has offices in Belgium, the United States, Japan, and Geneva. Visit us at www.argenx.com. Follow us on LinkedIn and Twitter.
AxoSim empowers advancements in human neuroscience by partnering with leading pharmaceutical and research institutions to facilitate therapeutic breakthroughs in the world’s most devastating neurodegenerative diseases.

The NerveSim® platform is the only in vitro model with Schwann cell myelination and human-relevant electrophysiological and structural data metrics, unlocking a powerful tool for human translation.

The BrainSim® platform is being developed to upend the way drugs are screened for myelin-related diseases of the CNS, such as multiple sclerosis and leukodystrophies.

With innovative drug discovery tools, AxoSim offers clinically-relevant data to select better lead candidates with functional, phenotypically accurate assays. AxoSim enables its partners to move safe and effective candidates toward the clinic faster than it has been done before.
Use of Immunoglobulin in the Individualized Management of CIDP

Trianon Ballroom, InterContinental Miami
Sunday, May 15, 2022, 7:15–8:15 PM

Agenda

Dr Amanda Peltier
Vanderbilt University Medical Center
Chair

Prof Marinos Dalakas
Thomas Jefferson University
Mechanisms of Action of Intravenous Immunoglobulin in CIDP

Dr Jeffery Allen
University of Minnesota
Will the New 2021 EAN/PNS Guideline Improve CIDP Diagnosis Accuracy?

Prof Mazen Dimachkie
University of Kansas Medical Center
Treatment of CIDP: How Far Have We Gone?

Followed by Interactive Audience Q&A session
Join Dr Sami L. Khella and our expert faculty for an in-depth discussion of the identification and management challenges of patients with mixed-phenotype ATTR amyloidosis.

Join Dr Sami Khella and our expert faculty for an in-depth discussion of the identification and management challenges of patients with ATTR-PN, ATTR-CM, and mixed-phenotype ATTR. Hear about the pathophysiology, diagnosis, and management of patients with ATTR amyloidosis from the neurologist’s and cardiologist’s perspectives. Faculty will also discuss the challenges of diagnosing ATTR amyloidosis with an emphasis on the benefits of a holistic and multidisciplinary approach to disease management.
Since its founding in 1909, Grifols has worked continuously to provide innovative medicines and solutions that improve the health and well-being of people around the world.
Pfizer invites you to attend a LIVE symposium at PNS 2022

An Intravenous Immunoglobulin Treatment With 2 FDA-Approved Maintenance Dosing Options for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Date: Monday, May 16, 2022
Time: 7:15 pm - 8:15 pm
Location: Trianon Ballroom

Presented by Dr Sami Khella, MD
Professor of Clinical Neurology, University of Pennsylvania School of Medicine, and Chief, Department of Neurology, Penn Presbyterian Medical Center

Visit our LIVE Pfizer Exhibit at Table #21

Or visit our Pfizer Ig Virtual Exhibit Booth at https://www.vr-exhibit.com/Pfizer/IG/2205
A Practical Approach to Diagnosis and Management of MMN: Past, Present and Future

May 16 2022, 7:15 – 8:15 pm, Versailles Ballroom

Join our experts in an interactive learning experience during which you will have the opportunity to learn about key challenges associated with multifocal motor neuropathy (MMN) and follow the patient journey.

<table>
<thead>
<tr>
<th>TIME (EDT)</th>
<th>TOPIC</th>
<th>FORMAT</th>
<th>SPEAKER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15 pm</td>
<td>Welcome, introductions and objectives</td>
<td>Plenary</td>
<td>Dr Jeffrey Allen</td>
</tr>
<tr>
<td>7:18 pm</td>
<td>What is MMN? Disease overview and pathophysiology</td>
<td>Plenary</td>
<td>Dr Norman Latov</td>
</tr>
<tr>
<td>7:33 pm</td>
<td>What is the future for diagnosing MMN? Overcoming challenges in current diagnostic approaches for MMN</td>
<td>Plenary</td>
<td>Dr Mamatha Pasnoor</td>
</tr>
<tr>
<td>7:48 pm</td>
<td>What are the unmet needs for patients with MMN? Following the patient journey</td>
<td>Case-based discussion</td>
<td>Dr Jeffrey Allen</td>
</tr>
<tr>
<td>8:03 pm</td>
<td>Q&amp;A session</td>
<td>Q&amp;A</td>
<td>All Faculty</td>
</tr>
<tr>
<td>8:15 pm</td>
<td>Meeting Close</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Learn from leading experts in a series of educational sessions

Dr Jeffrey Allen (Chair)
Associate Professor of Neurology
University of Minnesota
Minnesota, USA

Dr Norman Latov
Professor of Neurology
Weill Cornell Medicine
New York City, USA

Dr Mamatha Pasnoor
Professor of Neurology
University of Kansas Medical Center
Kansas, USA
Join us at a Breakfast Symposium sponsored by Alnylam Pharmaceuticals during the Peripheral Nerve Society 2022 Annual Meeting!

ABOUT THE PROGRAM*
Join our distinguished presenters as they discuss recognizing, diagnosing, and managing adult patients with polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. The presenters will also review the clinical profile for a treatment for the polyneuropathy of hATTR amyloidosis in adults.

SPEAKERS
Alejandra González-Duarte, MD
Associate Director and Associate Professor in the Department of Neurology
NYU Langone Health
New York, NY

Amanda Peltier, MD, MS
Chief of the Division of Neuromuscular Disorders,
Professor in the Department of Neurology and Medicine,
and Associate Vice Chair of Faculty Affairs
Vanderbilt University Medical Center
Nashville, TN

PROGRAM DATE & TIME
Monday, May 16, 2022
6:45 AM–7:45 AM ET

PROGRAM LOCATION
Intercontinental Miami, Chopin Ballroom,
Mezzanine Level

This event does not qualify for continuing education credit.

*Intended for US Healthcare Professionals only.

© 2022 Alnylam Pharmaceuticals, Inc. All rights reserved.   TTR-USA-00057
On-Demand Education Center

Preventing for what’s next in CIDP.

Janssen is committed to advancing the treatment of rare diseases, including new approaches to help patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Visit www.pnsociety.com to learn more about these exclusive member benefits!

On-Demand Education Center

PNS Communities Forum Join the discussion
Publishes original research reports, reviews, letters, and news covering every topic of scientific or clinical relevance to the peripheral nervous system.

Read, cite and submit your paper to JPNS

Publish with JPNS and experience the benefits:

- An expedient decision process and time to online publication, with article transfer option.
- A reputable journal, with a diverse and global editorial team, adding value for 20+ years.
- Global reach of researchers and practitioners at 13,000+ institutions.
- Expanded research impact through optional video abstract submission to accompany your article.

Publishing Open Access?
Your fees may be covered...
check now: https://bit.ly/APCfunders

Did you know? When compared to subscription articles, open access articles published by us receive, on average:

- 3.2X more downloads
- 1.5X more cites
- 4.7X higher Altmetric scores
- 2.7X higher Altmetric scores

Read the latest JPNS Special Issue
Images from the Nerve:
An Atlas for Neurologists
COPENHAGEN

PERIPHERAL NERVE SOCIETY

2023 ANNUAL MEETING

BELLA CENTER COPENHAGEN

SAVE THE DATE • 17-20 JUNE